Connection quality determination for wearable neurostimulation systems

Information

  • Patent Grant
  • 12251560
  • Patent Number
    12,251,560
  • Date Filed
    Thursday, August 13, 2020
    5 years ago
  • Date Issued
    Tuesday, March 18, 2025
    8 months ago
Abstract
Systems, devices, and methods for electrically stimulating peripheral nerve(s) to treat various disorders are disclosed, as well as signal processing systems and methods for enhancing diagnostic and therapeutic protocols relating to the same.
Description
BACKGROUND
Field

Embodiments of the invention relate generally to systems, devices, and methods for stimulating nerves, and more specifically relate to system, devices, and methods for electrically stimulating peripheral nerve(s) to treat various disorders, as well as signal processing systems and methods for enhancing diagnostic and therapeutic protocols relating to the same.


Description of the Related Art

A wide variety of modalities can be utilized to neuromodulate peripheral nerves. For example, electrical energy can be delivered transcutaneously or percutaneously via electrodes on the skin surface with neurostimulation systems to stimulate peripheral nerves, such as the median, radial, and/or ulnar nerves in the upper extremities; the tibial, saphenous, and/or peroneal nerve in the lower extremities; or the auricular vagus, tragus, trigeminal, occipital, or cranial nerves on the head or ear, as non-limiting examples. Stimulation of these nerves has been shown to provide therapeutic benefit across a variety of diseases, including but not limited to movement disorders (including but not limited to essential tremor, Parkinson's tremor, orthostatic tremor, and multiple sclerosis), urological disorders, gastrointestinal disorders, cardiac diseases, and inflammatory diseases, mood disorders (including but not limited to depression, bipolar disorder, dysthymia, and anxiety disorder), pain syndromes (including but not limited to migraines and other headaches, trigeminal neuralgia, fibromyalgia, complex regional pain syndrome), among others. A number of conditions, such as tremors, can be treated through some form of transcutaneous, percutaneous, or other implanted forms of peripheral nerve stimulation.


SUMMARY

Systems with compact, ergonomic form factors are needed to enhance efficacy, compliance, and/or comfort when using non-invasive or wearable neuromodulation devices. In several embodiments, neuromodulation systems and methods are provided that enhance or inhibit nerve impulses and/or neurotransmission, and/or modulate excitability of nerves, neurons, neural circuitry, and/or other neuroanatomy that affects activation of nerves and/or neurons. For example, neuromodulation (e.g., neurostimulation) can include one or more of the following effects on neural tissue: depolarizing the neurons such that the neurons fire action potentials; hyperpolarizing the neurons to inhibit action potentials; depleting neuron ion stores to inhibit firing action potentials; altering with proprioceptive input; influencing muscle contractions; affecting changes in neurotransmitter release or uptake; and/or inhibiting firing.


In some embodiments, disclosed here is a wearable neurostimulation device for transcutaneously stimulating one or more peripheral nerves of a user. The device can include, for example, any number of a plurality of electrodes configured to generate electric stimulation signals; and one or more hardware processors configured to: measure a plurality of distinct electromagnetic characteristics across the at least two electrodes; determine a plurality of connection quality indicators based on the measured plurality of electromagnetic characteristics, said connection quality indicators corresponding to a degree of connection between the at least two of the plurality of electrodes and skin of the user; update the plurality of connection quality indicators over a time window based on repeated measurements of the plurality of electromagnetic characteristics within the time window; determine that at least one of the plurality of connection quality indicators crosses a threshold within the time window; and/or change an operating characteristic of the wearable neurostimulation device based on the determination that the at least one of the plurality of connection quality indicators has crossed the threshold within the time window.


In some embodiments, the one or more hardware processors are configured to reset the plurality of connection quality indicators for a new time window.


In some embodiments, the one or more hardware processors are configured to maintain therapy during the time window where at least one of the plurality of connection quality indicators indicate a weak connection and where at least one of the plurality of connection quality indicators has not crossed the threshold.


In some embodiments, the electromagnetic characteristic comprises impedance.


In some embodiments, electromagnetic characteristic comprises voltage mismatch.


In some embodiments, the electromagnetic characteristic comprises a pulse shape In some embodiments, the operating characteristic includes stimulation settings.


In some embodiments, changing the operating characteristic includes generating an alert.


In some embodiments, each of the plurality of electromagnetic characteristics is configured to enable an independent determination of the connection quality indicator.


In some embodiments, disclosed herein is a method for monitoring the connection quality of a neurostimulation device. The method can include, for example, any number of the following: measuring a plurality of distinct electromagnetic characteristics across the at least two electrodes; determining a plurality of connection quality indicators based on the measured plurality of electromagnetic characteristics, said connection quality indicators corresponding to a degree of connection between the at least two of the plurality of electrodes and skin of the user; updating the plurality of connection quality indicators over a time window based on repeated measurements of the plurality of electromagnetic characteristics within the time window; determining that at least one of the plurality of connection quality indicators crosses a threshold within the time window; and changing an operating characteristic of the wearable neurostimulation device based on the determination that the at least one of the plurality of connection quality indicators has crossed the threshold within the time window.


In some embodiments, the method includes resetting the plurality of connection quality indicators for a new time window.


In some embodiments, the method includes maintaining therapy during the time window where at least one of the plurality of connection quality indicators indicate a weak connection and where at least one of the plurality of connection quality indicators has not crossed the threshold.


In some embodiments, the electromagnetic characteristic comprises impedance.


In some embodiments, the electromagnetic characteristic comprises voltage mismatch.


In some embodiments, the electromagnetic characteristic comprises a pulse shape determination.


In some embodiments, the operating characteristic includes stimulation settings.


In some embodiments, the changing the operating characteristic includes generating an alert.


In some embodiments, each of the plurality of electromagnetic characteristics is configured to enable an independent determination of the connection quality indicator.


In some embodiments, also disclosed herein is a wearable neurostimulation device for transcutaneously stimulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of electrodes configured to generate electric stimulation signals; and one or more hardware processors configured to: determine an electromagnetic characteristic across at least two of the plurality of electrodes; determine a connection quality indicator, corresponding to connection between the at least two of the plurality of electrodes and skin of the user, based on the determined electromagnetic characteristic; and/or change an operating characteristic of the wearable neurostimulation device based on the determined connection quality indicator.


In some embodiments, the electromagnetic characteristic comprises impedance.


In some embodiments, the electromagnetic characteristic comprises voltage mismatch.


In some embodiments, the electromagnetic characteristic comprises a pulse shape determination.


In some embodiments, the operating characteristic includes stimulation settings.


In some embodiments, the changing the operating characteristic includes generating an alert.


In some embodiments, the one or more hardware processors is configured to determine a plurality of electromagnetic characteristics across the at least two electrodes.


In some embodiments, each of the plurality of electromagnetic characteristics is configured to enable an independent determination of the connection quality indicator.


In some embodiments, the one or more hardware processors is configured to determine a plurality of connection quality indicators based on the determined plurality of electromagnetic characteristics.


In some embodiments, the one or more hardware processors is configured to track the determined plurality of connection quality indicators over a time period.


In some embodiments, the operating characteristic is only changed when at least one of the determined plurality of connection quality indicators exceed a threshold over the time period.


In some embodiments, disclosed herein is a wearable neurostimulation device for transcutaneously stimulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of electrodes configured to generate electric stimulation signals; and one or more hardware processors configured to: determine a plurality of electromagnetic characteristics across at least two of the plurality of electrodes; determine a plurality of connection quality indicators, corresponding to connection between the at least two of the plurality of electrodes and skin of the user, from each of the determined electromagnetic characteristic; track the plurality of connection quality indicators over a time window; and/or change an operating characteristic of the wearable neurostimulation device based on the tracking of the plurality of connection quality indicators.


In some embodiments, the plurality of electrodes comprise dry electrodes.


In some embodiments, the plurality of electrodes comprise a hydrogel.


In some embodiments, the plurality of electromagnetic characteristics comprise one or more of: impedance, voltage mismatch, and pulse shape determination.


In some embodiments, the one or more hardware processors is configured to track the plurality of connection quality indicators over a time window by maintaining one or more counters.


In some embodiments, the one or more hardware processors is configured to track the plurality of connection quality indicators over a time window by maintaining only a single counter based on the plurality of connection quality indicators.


In some embodiments, the one or more hardware processors is configured to change the operating characteristic of the wearable neurostimulation device if the plurality of connection quality indicators exceeds a threshold over the time window.


In some embodiments, the one or more hardware processors is configured to weight the plurality of connection quality indicators.


In some embodiments, the one or more hardware processors is configured to generate an alert to the patient.


In some embodiments, the one or more hardware processors is configured to change the operating characteristic of the wearable neurostimulation device by discontinuing stimulation.


In some embodiments, disclosed herein is a method for monitoring the connection quality of a neurostimulation device, that can include, for example, any number of the following: positioning a plurality of electrodes of the neurostimulation device on a skin of a user; delivering electrical stimulation transcutaneously through the plurality of electrodes; determining a plurality of electromagnetic characteristics across at least two of the plurality of electrodes; determining a plurality of connection quality indicators, corresponding to connection between the at least two of the plurality of electrodes and the skin of the user; tracking the plurality of connection quality indicators over a time window; and/or changing an operating characteristic of the wearable neurostimulation device if the plurality of connection quality indicators exceeds a threshold over the time window.


In some embodiments, the method includes determining a plurality of electromagnetic characteristics comprises determining one or more of impedance, voltage mismatch, and pulse shape.


In some embodiments, tracking the plurality of connection quality indicators comprises maintaining at least one counter of connection quality over the time window based on the plurality of connection quality indicators.


In some embodiments, tracking the plurality of connection quality indicators comprises maintaining only a single counter of connection quality over the time window based on the plurality of connection quality indicators.


In some embodiments, the method includes initializing a value of the counter after the end of the time window.


In some embodiments, the method includes altering a value of the counter based on at least one of the plurality of connection quality indicators.


In some embodiments, changing the operating characteristic comprises discontinuing delivering the electrical stimulation, and/or modifying the delivered electrical stimulation.


In some embodiments, modifying the delivered electrical stimulation comprises changing one or more of the frequency, voltage, current, or duration of the stimulation.


In some embodiments, the method also includes alerting the user to an abnormality in the connection quality.


In some embodiments, disclosed herein is a wearable neuromodulation device for transcutaneously modulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of effectors configured to generate neuromodulation signals; and one or more hardware processors configured to: determine a characteristic across at least two of the plurality of effectors; determine a connection quality indicator, corresponding to connection between the at least two of the plurality of effectors and skin of the user, based on the determined characteristic; and/or change an operating characteristic of the wearable neuromodulation device based on the determined connection quality indicator.


In some embodiments, disclosed herein is a wearable neuromodulation device for transcutaneously modulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of effectors configured to generate neuromodulation signals; and one or more hardware processors configured to: determine a plurality of characteristic across at least two of the plurality of effectors; determine a plurality of connection quality indicators, corresponding to connection between the at least two of the plurality of effectors and skin of the user, from each of the determined electromagnetic characteristic; track the plurality of connection quality indicators over a time window; and/or change an operating characteristic of the wearable neuromodulation device based on the tracking of the plurality of connection quality indicators.


In some embodiments, disclosed herein is a wearable neuromodulation device for transcutaneously modulating one or more peripheral nerves of a user. The device can include, for example, any number of the following: a plurality of electrodes configured to generate electric stimulation signals; and one or more hardware processors configured to: measure one, two, three, four, five, or more distinct electromagnetic characteristics across the at least two electrodes; determine one, two, three, four, five, or more connection quality indicators based on the measured one or more electromagnetic characteristics, said connection quality indicators corresponding to a degree of connection between the at least two, three, four, five, or more of the plurality of electrodes and skin of the user; update the one, two, or more connection quality indicators over a time window based on repeated measurements of the one, two, three, four, five, or more electromagnetic characteristics within the time window; determine that one, two, three, four, five, or more of the connection quality indicators crosses a threshold within the time window; and/or change an operating characteristic of the wearable neurostimulation device based on the determination that the one, two, three, four, five, or more of the connection quality indicators has crossed the threshold within the time window.


In some embodiments, disclosed herein is a neuromodulation device according to any one of the embodiments described in the disclosure. A device can, in some embodiments, comprise, consist essentially of, consist of, and/or not comprise any number of features as disclosed herein.


In some embodiments, disclosed herein is a method for tracking one or more connection quality indicators according to any one of the embodiments described in the disclosure.


In some embodiments, disclosed herein is a method for changing an operating characteristic of a wearable neuromodulation device based on tracking of a plurality of connection quality indicators.


In several embodiments, the embodiments described herein that, for example, monitor the connection quality of a neuromodulation system can have one or more of the following advantages: (i) greater therapeutic benefit with less discomfort (e.g., such as from electrical discharge from open circuits); (ii) less current use (e.g., less power and improved battery life); (iii) decreased device error alerts and interruptions in therapy (and thus delays in completing a therapy session); (iv) increased likelihood of patient compliance due to the foregoing; and/or (v) improving the sensitivity in the determination of when to generate the alert and/or stop delivery of the electrical stimulation to balance the safety of users with efficacy and comfort.


In some of the embodiments described herein, one, several or all of the following features are not included: (i) sensors configured to assess patient motion and/or collect motion data, (ii) accelerometers, gyroscopes, magnetometers, inertial measurement units. and (iii) EMG or other muscle sensors. In some embodiments, systems and methods are not configured for, or are not placed on the upper arm and/or are not configured for neuromodulation on the skin surface of the forehead. In some embodiments, systems and methods are not configured to, or do not modulate descending (e.g., efferent) nerve pathways, and only modulate ascending (e.g., afferent) nerve pathways. In some embodiments, systems and methods are not configured to, or do not modulate nerves only on the ventral side of the wrist. In some embodiments, systems and methods do not include any implantable components. In some embodiments, systems and methods are not configured for percutaneous or subcutaneous stimulation, and are only configured for transcutaneous neuromodulation. In some embodiments, systems and methods are not configured for only neuromodulating, e.g., stimulating the ventral side of the wrist, rather some configurations may neuromodulate, e.g., deliver stimulation between two or more of the ventral, dorsal, and/or lateral sides of the wrist to target the medial nerve.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A illustrates a block diagram of an example neuromodulation (e.g., neurostimulation) device.



FIG. 1B illustrates a block diagram of an embodiment of a controller that can be implemented with the hardware components described with respect to FIG. 1A.



FIG. 1C illustrates a block diagram of an embodiment of a controller.



FIG. 2 illustrates a flow chart of an embodiment of a process for determination of connection quality using impedance determination.



FIG. 3 illustrates a flow chart of an embodiment of a process for determination of connection quality using pulse shape determination.



FIG. 4 illustrates a flow chart of an embodiment of a process for determination of connection quality using voltage mismatch.



FIG. 5A illustrates a flow chart of an embodiment of a process for determination of connection quality.



FIG. 5B illustrates an architecture for determination of connection quality using more than one of the processes over time.



FIG. 5C illustrates a flow chart of an embodiment of a process for adding a time component to the processes discussed above.





DETAILED DESCRIPTION

Several embodiments disclosed herein relate to systems and methods for neuromodulation, including for example devices configured for providing neurostimulation. The neuromodulation (e.g., neurostimulation) devices provided herein may be configured to stimulate peripheral nerves of a user. The devices may be configured to transcutaneously transmit one or more neuromodulation (e.g., neurostimulation) signals across the skin of the user. In many embodiments, the devices are wearable devices configured to be worn by a user. The user may be a human, another mammal, or other animal user. A neuromodulation (e.g., neurostimulation) system is also provided in several embodiments and includes signal processing systems and methods for enhancing diagnostic and therapeutic protocols relating to the same. In some embodiments, the neuromodulation (e.g., neurostimulation) device is configured to be wearable on an upper extremity of a user (e.g., a wrist, forearm, arm, and/or finger(s) of a user). In some embodiments, the device is configured to be wearable on a lower extremity (e.g., ankle, calf, knee, thigh, foot, and/or toes) of a user. In some embodiments, the device is configured to be wearable on the head or neck (e.g., forehead, ear, neck, nose, and/or tongue). In several embodiments, dampening or blocking of nerve impulses and/or neurotransmitters are provided. In some embodiments, nerve impulses and/or neurotransmitters are enhanced.


In some embodiments, the device is configured to be wearable on or proximate an ear of a user, including but not limited to auricular neuromodulation (e.g., neurostimulation) of the auricular branch of the vagus nerve, for example. The device could be unilateral or bilateral, including a single device or multiple devices connected with wires or wirelessly.


In some embodiments, the neuromodulation (e.g., neurostimulation) devices and methods disclosed herein generally rely on a robust connection with the skin of the user. In some embodiments, the electrode material conforms to the irregularities on the skin surface to ensure a robust and proper electrical connection. Conformance of the electrode to the skin surface can be affected by properties of the electrode, including but not limited to shape, thickness, material compliance (e.g., stiffness or durometer), and/or adhesion properties. Particularly, due to an application of electrical stimulation, an improper connection can result, for example, in current concentration that may make the device inoperable and/or may be harmful or painful to the user. For example, current concentrations can occur as an electrode lifts from the skin surface thus reducing the area of contact and, if current delivered by the device is held constant, increasing the current density. The connection quality may vary based on user movement. The connection state or quality between the skin and the effectors, e.g., electrode(s) may also depend on the type material used for the electrodes. In some instances, to improve the quality of user experience, especially for all day wear or multiple reapplications, the effectors, e.g., electrodes, may not include an adhesive hydrogel material. While an adhesive hydrogel layer can improve conformance with the skin, the stickiness of the hydrogel can be uncomfortable for the user or collect dust and debris during wear. This can sometimes increase the risk of poor connection quality. In some embodiments, the wearer is instructed to wet the wrist or electrodes with water, gel, lotion, or another conductive medium to improve the connection at the skin interface. Without a proper connection between the neuromodulation device and the user, the overall efficacy can be reduced in some embodiments due to improper delivery of electrical stimulation to the appropriate nerve targets or reduced adherence with the recommended usage due to discomfort or device errors (e.g., device not operating normally). Accordingly, some of the systems and methods described herein improve the efficacy of treatment by determining the connection quality between the device and the user. It has been observed that an increase in device errors may cause some users to not comply with their therapy regime due to either frustration with the device or possible reduction in therapeutic effect. Accordingly, in some embodiments, increased connection quality results in enhanced comfort for the user and reduce number of device disconnection errors, thus increasing compliance or adherence.


When the quality of the connection between the neuromodulation (e.g., neurostimulation) device and the user is poor, the device can be programmed to halt the stimulation to avoid improper delivery of electrical stimulation. The device can be further programmed to alert a user of the poor quality connection. However, there may be instances where false positives are generated. For example, connection may be poor only for a small time period while the user is moving and then stabilize. However, if alerts are constantly generated when the connection is poor, this may adversely affect user experience. Moreover, if the stimulation/modulation is halted every time when there is some indication of poor connection quality, it may reduce the efficacy of the treatment, and/or causes delays in completing a therapy session. Accordingly, the systems and methods described herein improve the sensitivity in the determination of when to generate the alert and/or stop delivery of the electrical stimulation to balance the safety of users with efficacy and comfort.


Neuromodulation Device



FIG. 1A illustrates a block diagram of an example neuromodulation (e.g., neurostimulation) device 100. The device 100 includes multiple hardware components which are capable of, or programmed to provide therapy across the skin of the user. As illustrated in FIG. 1A, some of these hardware components may be optional as indicated by dashed blocks. In some instances, the device 100 may only include the hardware components that are required for stimulation therapy. The hardware components are described in more detail below.


The device 100 can include two or more effectors, e.g. electrodes 102 for providing neurostimulation signals. In some instances, the device 100 is configured for transcutaneous use only and does not include any percutaneous or implantable components. In some embodiments, the electrodes can be dry electrodes. In some embodiments, water or gel can be applied to the dry electrode or skin to improve conductance. In some embodiments, the electrodes do not include any hydrogel material, adhesive, or the like. The electrodes 102 can also be used to determine a connection quality as discussed below.


The device 100 can further include stimulation circuitry 104 for generating signals that are applied through the electrode(s) 102. The signals can vary in frequency, phase, timing, amplitude, or offsets. The device 100 can also include power electronics 106 for providing power to the hardware components. For example, the power electronics 106 can include a battery.


The device 100 can include one or more hardware processors 108. The hardware processors 108 can include microcontrollers, digital signal processors, application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. In an embodiment, all of the processing discussed herein is performed by the hardware processor(s) 108. The memory 110 can store data specific to patient and rules as discussed below.


In the illustrated figure, the device 100 can include one or more sensors 112. As shown in the figure, the sensor(s) 112 may be optional. Sensors could include, for example, biomechanical sensors configured to, for example, measure motion, and/or bioelectrical sensors (e.g., EMG, EEG, and/or nerve conduction sensors). Sensors can include, for example, cardiac activity sensors (e.g., ECG, PPG), skin conductance sensors (e.g., galvanic skin response, electrodermal activity), and motion sensors (e.g., accelerometers, gyroscopes). The one or more sensors 102 may include an inertial measurement unit (IMU).


In some embodiments, the IMU can include one or more of a gyroscope, accelerometer, and magnetometer, which may also be used to determine connection quality. The IMU can be affixed or integrated with the neuromodulation (e.g., neurostimulation) device 100. In an embodiment, the IMU is an off the shelf component. In addition to its ordinary meaning, the IMU can also include specific components as discussed below. For example, the IMU can include one more sensors capable of collecting motion data. In an embodiment, the IMU includes an accelerometer. In some embodiments, the IMU can include multiple accelerometers to determine motion in multiple axes. Furthermore, the IMU can also include one or more gyroscopes and/or magnetometer in additional embodiments. Since the IMU can be integrated with the neurostimulation device 100, the IMU can generate data from its sensors responsive to motion, movement, or vibration felt by the device 100. Furthermore, when the device 100 with the integrated IMU is worn by a user, the IMU can enable detection of voluntary and/or involuntary motion of the user.


The device 100 can optionally include user interface components, such as a feedback generator 114 and a display 116. The display 116 can provide instructions or information to users relating to calibration or therapy. The display 116 can also provide alerts, such an indication of poor connection quality or band not connected. Alerts may also be provided using the feedback generator 114, which can provide haptic feedback to the user, such as upon initiation or termination of stimulation, for reminder alerts, to alert the user of a troubleshooting condition such as connection quality, to perform a tremor inducing activity to measure tremor motion, among others. Accordingly, the user interface components, such as the feedback generator 114 and the display 116 can provide audio, visual, and haptic feedback to the user.


Furthermore, the device 100 can include communications hardware 118 for wireless or wired communication between the device 100 and an external system, such as the user interface device discussed below. The communications hardware 118 can include an antenna. The communications hardware 118 can also include an Ethernet or data bus interface for wired communications.


While the illustrated figure shows several components of the device 100, some of these components are optional and not required in all embodiments of the device 100. In some embodiments, a system can include a diagnostic device or component that does not include neuromodulation functionality. The diagnostic device could be a companion wearable device connected wirelessly through a connected cloud server, and include, for example, sensors such as cardiac activity, skin conductance, and/or motion sensors as described elsewhere herein.


In some embodiments, the device 100 can also be configured to deliver one, two or more of the following: magnetic, vibrational, mechanical, thermal, ultrasonic, or other forms of stimulation instead of, or in addition to electrical stimulation. Such stimulation can be delivered via one, two, or more effectors in contact with, or proximate the skin surface of the patient. However, in some embodiments, the device is configured to only deliver electrical stimulation, and is not configured to deliver one or more of magnetic, vibrational, mechanical, thermal, ultrasonic, or other forms of stimulation.


Although several neurostimulation devices are described herein, in some embodiments nerves are modulated non-invasively to achieve neuro-inhibition. Neuro-inhibition can occur in a variety of ways, including but not limited to hyperpolarizing the neurons to inhibit action potentials and/or depleting neuron ion stores to inhibit firing action potentials. This can occur in some embodiments via, for example, anodal or cathodal stimulation, low frequency stimulation (e.g., less than about 5 Hz in some cases), or continuous or intermediate burst stimulation (e.g., theta burst stimulation). In some embodiments, the wearable devices have at least one implantable portion, which may be temporary or more long term. In many embodiments, the devices are entirely wearable and non-implantable.


User Interface Device



FIG. 1B illustrates communications between the neurostimulation device 100 and a user interface device 150 over a communication link 130. The communication link 130 can be wired or wireless. The neuromodulation (e.g., neurostimulation) device 100 is capable of communicating and receiving instructions from a user interface device 150. The user interface device 150 can include a computing device. In some embodiments, the user interface device 150 is a mobile computing device, such as a mobile phone, a smartwatch, a tablet, or a wearable computer. The user interface device 150 can also include server computing systems that are remote from the neurostimulation device. The user interface device 150 can include hardware processor(s) 152, a memory 154, display 156, and power electronics 158. In some embodiments, a user interface device 150 can also include one or more sensors, such as sensors described elsewhere herein. Furthermore, in some instances, the user interface device 150 can generate an alert responsive to connection quality between the electrodes and skin of the patient. The alert may be received from the neurostimulation device 100.


In additional embodiments, data acquired from the one or more sensors 102 is processed by a combination of the hardware processor(s) 108 and hardware processor(s) 152. In further embodiments, data collected from one or more sensors 102 is transmitted to the user interface device 150 with little or no processing performed by the hardware processors 108. In some embodiments, the user interface device 150 can include a remote server that processes data and transmits signals back to the device 100 (e.g., via the cloud).


Controller



FIG. 1C illustrates a block diagram of an embodiment of a controller 160. The controller 160 can include one or more software engines for performing the processes and functions described herein. The software engines can include programmed instructions for performing processes as discussed herein (and illustrated in flowcharts) for detection of input conditions and control of output conditions based on determination of connection quality. The engines can be executed by the one or more hardware processors of the neurostimulation device 100 alone or in combination with the user interface device 150. The programming instructions can be stored in a memory 110. The programming instructions can be implemented in C, C++, JAVA, or any other suitable programming languages. In some embodiments, some or all of the portions of the controller 200 including the engines can be implemented in application specific circuitry such as ASICs and FPGAs. Some aspects of the functionality of the controller 200 can be executed remotely on a server (not shown) over a network. Accordingly, the controller 160 can be implemented with the hardware components described above with respect to FIG. 1A.


Impedance Determination



FIG. 2 illustrates a flowchart of an example process 200 for determining connection quality using impedance. The process 200 can be implemented by any of the systems discussed above. The process 200 can be implemented alone or in combination with other processes described below.


The impedance determination process 200 can begin at block 202 with measuring impedance between any two electrodes of the neurostimulation device 100. The determination of impedance can indicate a presence of an open circuit. For example, when there is a poor connection between the electrodes and the skin, the impedance value may be high, corresponding to an open circuit. Such high impedance can result in an improper delivery of electrical stimulation, such as an increase in current density. Accordingly, the impedance measurement can be used to determine connection quality between the electrodes and the skin. In some instances, impedance can be measured for some or all pairs of the electrodes 102.


At block 204, the controller 160 can compare the measured impedance with an impedance threshold value. This threshold value might be stored in the memory 110. Based on the comparison, the controller 160 can determine connection quality between the electrodes and the skin of the patient. The impedance for a skin is generally about 4 kΩ. The threshold value can be a factor of the general skin impedance. Example values include about, at least about, or no more than about 8 kΩ, 20 kΩ, 40 kΩ, 50 kΩ, or about 100 kΩ, or ranges including any two of the foregoing values. In some instances, the threshold value is at least about 4 kΩ. If the comparison indicates an open circuit condition, the controller 160 can set connection quality to be low or poor. The connection quality can be a numeric indicator. The numeric indicator can represent a degree of quality of connection. In some instances, the connection quality can be a binary indicator, indicating true (1) or false (0) for whether the connection quality is good or bad. The connection quality can also be a textual indicator, such as “Band Not Connected.” The connection quality indicator can be used by the controller 160 to determine output conditions as discussed in more detail below with respect to FIG. 5. Output conditions can include alerts and/or control of the neurostimulation device 100. For example, output conditions can include halting the stimulation, changing a characteristic of the stimulation, or maintaining a current stimulation treatment. In some instances, the controller 160 can use the impedance detection process 200 by itself to determine the connection quality indicator and control output conditions.


Pulse Shape Determination



FIG. 3 illustrates a flowchart of an example process 300 for determining connection quality using pulse shape. The process 300 can be implemented by any of the systems discussed above. The process 300 can be implemented alone or in combination with other processes described herein, such as the impedance determination process 200.


The pulse shape determination process 300 can begin at block 302 with a transmission of a pulse having a particular shape across any two electrodes of the neurostimulation device 100. In some instances, the pulse shape can correspond to a positive pulse. In other instances, the pulse shape can correspond to a negative pulse. In other instances, the pulse shape can correspond to a positive and a negative pulse, with an interpulse interval. The pulse shape can also be gaussian or any other profile. The controller 160 can use predetermined pulse shapes stored in the memory 110. The controller 160 can cause the transmission of the pulse at block 302.


When the connection quality is poor, the pulse shape is distorted as it is transmitted across the electrodes. Higher distortion generally corresponds to poor quality connection. Accordingly, the controller 160 can determine the change in the profile of the pulse that was transmitted. In some instances, the change is determined based on the area under the curve of the received pulse. In some instances, the change is determined based on features of the pulse in the time domain, such pulse width or pulse amplitude. The change may also be determined based on a phase of the waveform. Further, the change may also be determined based on duration or time points of wave shape. The change can also be determined based on cross-correlation of the transmitted and received pulse or any other suitable signal processing techniques. In some instances, about or at least about 10%, 15%, 20%, 25%, 30%, or more change in pulse shape or pulse shape features is used as a threshold to determine connection quality indicator. Other values of thresholds can be used to adjust sensitivity.


Based on the change in pulse profile, the controller 160 can determine the connection quality between the electrodes and the skin at block 306. As discussed above, the connection quality can be a numeric, binary, or a textual indicator. The connection quality indicator can be used by the controller 160 to determine output conditions as discussed in more detail below with respect to FIG. 5. In some instances, the controller 160 can use the pulse shape determination process 300 by itself to determine the connection quality indicator and control output conditions.


Voltage Mismatch Determination



FIG. 4 illustrates a flowchart of an example process 400 for determining connection quality using voltage mismatch. The process 400 can be implemented by any of the systems discussed above. The process 400 can be implemented alone or in combination with other processes described herein, such as the impedance determination process 200 and/or the pulse shape determination process 300.


In several embodiments, the pulse shape determination process 400 can begin at block 402 with a determination of voltage across any two electrodes of the neurostimulation device 100. In some instances, the controller 160 can test the voltage difference across two electrodes. The actual voltage measured can be a function of connection quality between the electrodes and skin. If the connection quality is good, the actual voltage measured will be close to the expected value. In contrast, for a poor quality connection the actual voltage may deviate from the expected value. Accordingly, the controller 160 can compare the measured voltage with the expected voltage at block 404. Example values of thresholds for the voltage difference include about 5 k mV, about 10 k mV, about 50 k mV, about 70 k mV, and about 100 k mV or more or less, or ranges including any two of the foregoing values.


Based on the comparison, the controller 160 can determine an indication of connection quality between the electrodes and the skin at block 406. In some instances, the controller 160 can use the voltage mismatch determination process 300 by itself to determine the connection quality indicator and control output conditions.


Connection Quality Indicator Determination



FIG. 5A illustrates an example process 500 for determination of connection quality indicator. The process 500 can be implemented by any of the systems described above. The process 500 can incorporate any of the processes discussed above with respect to FIGS. 2 to 4.


That is, at block 502, the controller 160 can measure an electromagnetic characteristic between two electrodes. The electromagnetic characteristic can include voltage mismatch, impedance determination, or pulse shape determination as discussed above. In some embodiments, the electromagnetic characteristic does not include one or more of voltage mismatch, impedance determination, or pulse shape determination. Other electromagnetic characteristics can include signal quality of delivered current, including but not limited to signal to noise ratio.


At block 504, the controller 160 can compare the measured electrode characteristic with an expected value. For example, the controller 160 can compare the measured values with stored thresholds to identify an open circuit, or pulse shape distortion, or voltage mismatch as discussed above.


Based on the comparison, the controller 160 can determine connection quality indicator between one of the electrodes and skin of the patient at block 506. As discussed above, the connection quality indicator can be a numeric, binary, or a textual indicator. The connection quality indicator can be used by the controller 160 to determine output conditions. Output conditions can include alerts and/or control of the neurostimulation device 100. Alerts can include haptic feedback, visual display, and halting stimulation. For example, output conditions can include halting the stimulation, changing a characteristic of the stimulation, or maintaining current stimulation treatment.


Accumulation Dissipation (AD) Determination


The controller 160 can use any of the processes 200, 300, or 400 discussed above individually or in combination to determine connection quality and control output conditions. However, changing an output condition based on the determination of the connection quality from one of the processes instantaneously or relative instantaneously can result in false alarms or unnecessarily high sensitivity to connection condition. FIG. 5B illustrates an architecture for combining the processes 200, 300, and 400 and adding a time component (or persistence) with the AD determination 520 (discussed in detail with respect to FIG. 5C) before executing a change the output condition.


The AD determination 520 can use outputs from some or all of the processes described above as shown in FIG. 5B. The outputs may be weighted equally or unequally. In some instances, the AD determination 520 can receive outputs from multiple pulse shape determinations processes 300, each including a different pulse shape. In one example, the AD determination 500 uses a positive pulse and a negative pulse as the transmitted pulses in the pulse shape determinations processes 400. The AD determination 520 can also use other signals 550 to determine output conditions. For example, the accelerometer data from IMU 102 can be used the by controller 160 to determine sudden movements by the user. The controller 160 can correlate the movement data with the connection quality indicator data received from one of the processes discussed above. Other signals 550 can also include user inputs indicating their preference on connection quality threshold and when to change the output conditions.


The output conditions can include, for example, generating an alert, changing neuromodulation (e.g., stimulation) properties, halting the neuromodulation (e.g., stimulation), or maintaining neuromodulation (e.g., stimulation). The time component will be described below with respect to FIG. 5C.



FIG. 5C illustrates a flowchart of an example process 520 for AD determination that adds time component to the processes discussed above. The process 520 can be implemented by any of the systems discussed above.


At block 522, the controller 160 can receive connection quality indicators from the one or more processes 200-400 discussed above. In some examples, as illustrated in block 524, the controller 160 can maintain one or more counters in the memory 110 corresponding to overall connection quality based on the received connection quality indicators from each of the processes shown in FIG. 5A. In one example, a single counter is used by the controller 160 to determine overall connection quality. When one of the processes 200-400 as shown in FIG. 5A indicates a poor connection quality, the controller 160 can increase the counter by 1. If one of the processes outputs a good connection quality indicator, the counter can be decreased by 1. The poor and good are relative terms. As discussed above, the connection quality indicators can be numeric, binary, or textual. While the counters are described in terms of integers and changing in a particular direction, this is relative and other means for tracking can be used.


In some instances, the controller 160 can maintain separate counters for each of the processes illustrated in FIG. 5A. That is, whenever a connections quality indicator is good or bad for a respective process, the respective counter for that process is increased or decreased accordingly by the controller 160. These counters can be stored in the memory 110.


At block 526, the controller 160 can compare the one or more counters to respective one or more threshold. If a single counter is used, the controller 160 compares the single counter with the threshold. When the counter exceeds a threshold, the controller 160 can generate an output condition as shown in block 528. If multiple counters are used, such as a counter for each of the processes input, the controller 160 can compare each of these counters with its respective threshold value. In one example, if any one of the counters exceed their respective threshold, the controller 160 can generate an output condition as shown in block 508. If the counters are within their limits, the controller 160 can continue monitoring the connection quality. In some instances, the controller 160 can poll one or more processes discussed above in a loop at regular intervals. Further, in some examples, the processes can run in parallel and send an indication at regular intervals.


In some instances, the time window is 125 milliseconds, 250 milliseconds, or 500 milliseconds, or more or less. The one or more counters may be initialized to zero at the start of a new time period. The time window can also be continuous. Thus, in some instances, the counters are not initialized after any particular time and maintained throughout the therapy time. Furthermore, in some cases, the threshold count is 64. In other examples, the threshold count can be 128 or higher. In additional examples, the threshold count can be less than 64, between about 32 and 512, or about 32, 64, 128, 256, 512, or ranges including any two of the foregoing values. The users may also be able to set threshold count based on their preferences. Output condition can include changing properties of the stimulation (for example, frequency, voltage, current, duration); halting the stimulation, or generating an alert that can be visual, auditory, or haptic.


Thus, based on the AD determination 520, the controller 160 can adjust or tune when to change the output or operating condition of the neurostimulation device 100 to balance between safety and efficacy. The threshold counts, like threshold values discussed above, can be adjusted to change sensitivity. For example, increasing the threshold count can make the neurostimulation device 100 less sensitive to connection quality errors, while decreasing the threshold count can make the neurostimulation device 100 more sensitive to connection quality errors. In some instances, the threshold counts and values can be set externally by a hospital or manufacturer and can be updated remotely.


Terminology


When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. References to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.


Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising.” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.


Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.


Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.


Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.


As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately.” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.


Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.


The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “percutaneously stimulating an afferent peripheral nerve” includes “instructing the stimulation of an afferent peripheral nerve.”

Claims
  • 1. A wearable neurostimulation device for transcutaneously stimulating one or more peripheral nerves of a user, the device comprising: circuitry for generating electric stimulation signals;a plurality of electrodes configured to emit the electric stimulation signals; andone or more hardware processors configured to: measure a plurality of electromagnetic characteristics across at least two of the plurality of electrodes,wherein the at least two of the plurality of electrodes comprises a first electrode and a second electrode,wherein the plurality of electromagnetic characteristics comprises a first electromagnetic characteristic of the first electrode, andwherein the plurality of electromagnetic characteristics comprises a second electromagnetic characteristic of the second electrode;determine a plurality of connection quality indicators based on the first electromagnetic characteristic and the second electromagnetic characteristic, said connection quality indicators corresponding to a degree of connection between the first electrode and the second electrode with skin of the user;maintain one or more counters for the plurality of connection quality indicators over a time window based on repeated measurements of the plurality of electromagnetic characteristics within the time window;wherein maintaining one or more counters for the plurality of connection quality indicators comprises determining if at least one of the one or more counters crosses a threshold within the time window; andchange an operating characteristic of the wearable neurostimulation device if at least one of the one or more counters has crossed the threshold within the time window;wherein the one or more hardware processors are capable of determining the plurality of connection quality indicators based on the plurality of electromagnetic characteristics.
  • 2. The wearable neurostimulation device of claim 1, wherein the one or more hardware processors are configured to reset the one or more counters after the time window has elapsed.
  • 3. The wearable neurostimulation device of claim 1, wherein the one or more hardware processors are configured to maintain therapy during the time window where at least one of the plurality of connection quality indicators indicate a weak connection and where at least one of the plurality of connection quality indicators has not crossed the threshold.
  • 4. The wearable neurostimulation device of claim 1, wherein the electromagnetic characteristic comprises impedance.
  • 5. The wearable neurostimulation device of claim 1, wherein the electromagnetic characteristic comprises voltage mismatch.
  • 6. The wearable neurostimulation device of claim 1, wherein the electromagnetic characteristic comprises a pulse shape determination.
  • 7. The wearable neurostimulation device of claim 1, wherein the operating characteristic includes stimulation settings.
  • 8. The wearable neurostimulation device of claim 1, wherein the changing the operating characteristic includes generating an alert.
  • 9. The wearable neurostimulation device of claim 1, wherein each of the plurality of electromagnetic characteristics is configured to enable an independent determination of the connection quality indicator independent of at least one other determination of the connection quality indicator.
  • 10. A wearable neurostimulation device for transcutaneously stimulating one or more peripheral nerves of a user, the device comprising: circuitry for generating electric stimulation signals;a plurality of electrodes configured to emit the electric stimulation signals; andone or more hardware processors configured to: determine a first electromagnetic characteristic across a first electrode of the plurality of electrodes and a second electromagnetic characteristic across a second electrode of the plurality of electrodes;determine a first connection quality indicator, corresponding to connection between the first electrode of the plurality of electrodes and skin of the user, based on the determined electromagnetic characteristic;determine a second connection quality indicator, corresponding to connection between the second electrode of the plurality of electrodes and skin of the user, based on the determined electromagnetic characteristic;maintain a first counter corresponding to the first connection quality indicator over a time window, wherein the first counter can increase or decrease during the time window based on the connection quality indicator;maintain a second counter corresponding to the second connection quality indicator over a time window, wherein the first counter can increase or decrease during the time window based on the connection quality indicator; andchange an operating characteristic of the wearable neurostimulation device based on either the first counter or the second counter exceeding a threshold.
  • 11. The wearable neurostimulation device of claim 10, wherein the electromagnetic characteristic comprises impedance.
  • 12. The wearable neurostimulation device of claim 10, wherein electromagnetic characteristic comprises voltage mismatch.
  • 13. The wearable neurostimulation device of claim 10, wherein electromagnetic characteristic comprises a pulse shape determination.
  • 14. The wearable neurostimulation device of claim 10, wherein the operating characteristic includes stimulation settings.
  • 15. The wearable neurostimulation device of claim 10, wherein the changing the operating characteristic includes generating an alert.
  • 16. The wearable neurostimulation device of claim 10, wherein the one or more hardware processors is configured to determine a plurality of electromagnetic characteristics across the plurality of electrodes, wherein each of the plurality of electromagnetic characteristics is configured to enable an independent determination of the connection quality indicator.
  • 17. The wearable neurostimulation device of claim 16, wherein the one or more hardware processors is configured to determine a plurality of connection quality indicators based on the determined plurality of electromagnetic characteristics.
  • 18. The wearable neurostimulation device of claim 17, wherein the one or more hardware processors is configured to track the determined plurality of connection quality indicators over a time period.
  • 19. The wearable neurostimulation device of claim 18, wherein the operating characteristic is only changed when at least one of the determined plurality of connection quality indicators exceed a threshold over the time period.
REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119 (e) to U.S. Prov. App. No. 62/886,218 filed on Aug. 13, 2019, which is hereby incorporated by reference in its entirety.

US Referenced Citations (862)
Number Name Date Kind
3204637 Frank et al. Sep 1965 A
3870051 Brindley Mar 1975 A
4103808 Hallman et al. Aug 1978 A
4300575 Wilson Nov 1981 A
4458696 Larimore Jul 1984 A
4461075 Bailey Jul 1984 A
4539996 Engel Sep 1985 A
4569351 Tang Feb 1986 A
4582049 Ylvisaker Apr 1986 A
4729377 Granek et al. Mar 1988 A
4739764 Lue et al. Apr 1988 A
4763659 Dunseath, Jr. Aug 1988 A
4771779 Tanagho et al. Sep 1988 A
4981146 Bertolucci Jan 1991 A
4982432 Clark et al. Jan 1991 A
4996987 Petrofsky Mar 1991 A
5003978 Dunseath, Jr. Apr 1991 A
5052391 Silverstone et al. Oct 1991 A
5070862 Berlant Dec 1991 A
5137507 Park Aug 1992 A
5330516 Nathan Jul 1994 A
5397338 Grey et al. Mar 1995 A
5514175 Kim et al. May 1996 A
5540235 Wilson Jul 1996 A
5562707 Prochazka et al. Oct 1996 A
5562717 Tippey et al. Oct 1996 A
5573011 Felsing Nov 1996 A
5575294 Perry et al. Nov 1996 A
5606968 Mang Mar 1997 A
5643173 Welles Jul 1997 A
5775331 Raymond et al. Jul 1998 A
5833709 Rise et al. Nov 1998 A
5833716 Bar-Or et al. Nov 1998 A
5899922 Loos May 1999 A
6016449 Fischell et al. Jan 2000 A
6076018 Sturman et al. Jun 2000 A
6081744 Loos Jun 2000 A
6161044 Silverstone Dec 2000 A
6178352 Gruzdowich et al. Jan 2001 B1
6351674 Silverstone Feb 2002 B2
6366813 DiLorenzo Apr 2002 B1
6366814 Boveja et al. Apr 2002 B1
6445955 Michelson et al. Sep 2002 B1
6449512 Boveja Sep 2002 B1
6453204 Rhoads Sep 2002 B1
6505074 Boveja et al. Jan 2003 B2
6546290 Shloznikov Apr 2003 B1
6564103 Fischer et al. May 2003 B2
6579270 Sussman et al. Jun 2003 B2
6652449 Gross et al. Nov 2003 B1
6678548 Echauz et al. Jan 2004 B1
6701185 Burnett et al. Mar 2004 B2
6704603 Gesotti Mar 2004 B1
6731987 McAdams et al. May 2004 B1
6735474 Loeb et al. May 2004 B1
6735480 Giuntoli et al. May 2004 B2
6788976 Gesotti Sep 2004 B2
6819956 DiLorenzo Nov 2004 B2
6829510 Nathan et al. Dec 2004 B2
6836684 Rijkhoff et al. Dec 2004 B1
6862480 Cohen et al. Mar 2005 B2
6892098 Ayal et al. May 2005 B2
6937905 Carroll et al. Aug 2005 B2
6959215 Gliner et al. Oct 2005 B2
6959216 Faghri Oct 2005 B2
6988005 McGraw et al. Jan 2006 B2
7010352 Hogan Mar 2006 B2
7089061 Grey Aug 2006 B2
7146220 Dar et al. Dec 2006 B2
7162305 Tong et al. Jan 2007 B2
7171266 Gruzdowich et al. Jan 2007 B2
7177694 Elbaum Feb 2007 B2
7177703 Boveja et al. Feb 2007 B2
7209787 DiLorenzo Apr 2007 B2
7228178 Carroll et al. Jun 2007 B2
7231254 DiLorenzo Jun 2007 B2
7236830 Gliner Jun 2007 B2
7254444 Moore et al. Aug 2007 B2
7277758 DiLorenzo Oct 2007 B2
7324851 DiLorenzo Jan 2008 B1
7326235 Edwards Feb 2008 B2
7328068 Spinelli et al. Feb 2008 B2
7349739 Harry et al. Mar 2008 B2
7353064 Gliner et al. Apr 2008 B2
7369896 Gesotti May 2008 B2
7499747 Kieval et al. Mar 2009 B2
7529582 DiLorenzo May 2009 B1
7558610 Odderson Jul 2009 B1
7636602 Baru Fassio et al. Dec 2009 B2
7643880 Tanagho et al. Jan 2010 B2
7643882 Boston Jan 2010 B2
7647112 Tracey et al. Jan 2010 B2
7650190 Zhou et al. Jan 2010 B2
7657317 Thacker et al. Feb 2010 B2
7742820 Wyler et al. Jun 2010 B2
7761166 Giftakis et al. Jul 2010 B2
7769464 Gerber et al. Aug 2010 B2
7857771 Alwan et al. Dec 2010 B2
7899527 Yun et al. Mar 2011 B2
7899556 Nathan et al. Mar 2011 B2
7917201 Gozani et al. Mar 2011 B2
7930034 Gerber Apr 2011 B2
7949403 Palermo et al. May 2011 B2
7957814 Goetz et al. Jun 2011 B2
7974696 DiLorenzo Jul 2011 B1
7974698 Tass et al. Jul 2011 B2
7991476 Nachum Aug 2011 B2
7996088 Marrosu et al. Aug 2011 B2
7998092 Avni et al. Aug 2011 B2
8000796 Tass et al. Aug 2011 B2
8025632 Einarsson Sep 2011 B2
8046083 Teganthoff et al. Oct 2011 B2
8075499 Nathan et al. Dec 2011 B2
8086318 Strother et al. Dec 2011 B2
8121694 Molnar et al. Feb 2012 B2
8145316 Deem et al. Mar 2012 B2
8165668 Dacey, Jr. et al. Apr 2012 B2
8165685 Knutson et al. Apr 2012 B1
8170658 Dacey, Jr. et al. May 2012 B2
8175718 Wahlgren et al. May 2012 B2
8187209 Guiffrida et al. May 2012 B1
8190249 Gharieb et al. May 2012 B1
8195287 Dacey, Jr. et al. Jun 2012 B2
8209036 Nathan et al. Jun 2012 B2
8219188 Craig Jul 2012 B2
8233988 Errico et al. Jul 2012 B2
8260439 Diubaldi et al. Sep 2012 B2
8265763 Fahey Sep 2012 B2
8301215 Lee Oct 2012 B2
8306624 Gerber et al. Nov 2012 B2
8308665 Harry et al. Nov 2012 B2
8313443 Tom Nov 2012 B2
8326432 Kalisek Dec 2012 B2
8343026 Gardiner et al. Jan 2013 B2
8364257 Van Den Eerenbeemd et al. Jan 2013 B2
8374701 Hyde et al. Feb 2013 B2
8380314 Panken et al. Feb 2013 B2
8382688 Dar et al. Feb 2013 B2
8391970 Tracey et al. Mar 2013 B2
8396556 Libbus et al. Mar 2013 B2
8406841 Lin et al. Mar 2013 B2
8409116 Wang et al. Apr 2013 B2
8412338 Faltys Apr 2013 B2
8414507 Asada Apr 2013 B2
8417351 Kilger Apr 2013 B2
8428719 Napadow Apr 2013 B2
8430805 Burnett et al. Apr 2013 B2
8435166 Burnett et al. May 2013 B2
8447411 Skelton et al. May 2013 B2
8452410 Emborg et al. May 2013 B2
8463374 Hudson et al. Jun 2013 B2
8473064 Castel et al. Jun 2013 B2
8548594 Thimineur et al. Oct 2013 B2
8571687 Libbus et al. Oct 2013 B2
8581731 Purks et al. Nov 2013 B2
8583238 Heldman et al. Nov 2013 B1
8588884 Hegde et al. Nov 2013 B2
8588917 Whitehurst et al. Nov 2013 B2
8608671 Kinoshita et al. Dec 2013 B2
8626305 Nielsen et al. Jan 2014 B2
8639342 Possover Jan 2014 B2
8644904 Chang et al. Feb 2014 B2
8644938 Craggs Feb 2014 B2
8660656 Moser et al. Feb 2014 B2
8666496 Simon et al. Mar 2014 B2
8679038 Giuffrida Mar 2014 B1
8682441 De Ridder Mar 2014 B2
8688220 Degiorgio et al. Apr 2014 B2
8694104 Libbus et al. Apr 2014 B2
8694110 Nathan et al. Apr 2014 B2
8702584 Rigaux et al. Apr 2014 B2
8702629 Giuffrida et al. Apr 2014 B2
8706241 Firlik et al. Apr 2014 B2
8718780 Lee May 2014 B2
8738143 Tucker et al. May 2014 B2
8740825 Ehrenreich et al. Jun 2014 B2
8744587 Miesel et al. Jun 2014 B2
8755892 Amurthur et al. Jun 2014 B2
8768452 Gerber Jul 2014 B2
8788045 Gross et al. Jul 2014 B2
8788049 Lasko et al. Jul 2014 B2
8792977 Kakei et al. Jul 2014 B2
8798698 Kim et al. Aug 2014 B2
8821416 Johansson et al. Sep 2014 B2
8825163 Grill et al. Sep 2014 B2
8825165 Possover Sep 2014 B2
8843201 Heldman et al. Sep 2014 B1
8845494 Whitall et al. Sep 2014 B2
8845557 Giuffrida et al. Sep 2014 B1
8855775 Leyde Oct 2014 B2
8862238 Rahimi et al. Oct 2014 B2
8862247 Schoendorf et al. Oct 2014 B2
8868177 Simon et al. Oct 2014 B2
8874227 Simon et al. Oct 2014 B2
8880175 Simon Nov 2014 B2
8886321 Rohrer et al. Nov 2014 B2
8892200 Wagner et al. Nov 2014 B2
8897870 De Ridder Nov 2014 B2
8903494 Goldwasser et al. Dec 2014 B2
8920345 Greenberg et al. Dec 2014 B2
8923970 Bar-Yoseph et al. Dec 2014 B2
8948876 Gozani et al. Feb 2015 B2
8961439 Yang et al. Feb 2015 B2
8972017 Dar et al. Mar 2015 B2
8989861 Su et al. Mar 2015 B2
9002477 Burnett Apr 2015 B2
9005102 Burnett et al. Apr 2015 B2
9008781 Ahmed Apr 2015 B2
9011310 Ahmed Apr 2015 B2
9017273 Burbank et al. Apr 2015 B2
9026216 Rossi et al. May 2015 B2
9042988 Dilorenzo May 2015 B2
9060747 Salorio Jun 2015 B2
9089691 Libbus et al. Jul 2015 B2
9095351 Sachs et al. Aug 2015 B2
9095417 Dar et al. Aug 2015 B2
9107614 Halkias et al. Aug 2015 B2
9119964 Marnfeldt Sep 2015 B2
9155885 Wei et al. Oct 2015 B2
9155890 Guntinas-Lichius et al. Oct 2015 B2
9162059 Lindenthaler Oct 2015 B1
9168374 Su Oct 2015 B2
9174045 Simon et al. Nov 2015 B2
9186095 Machado et al. Nov 2015 B2
9192763 Gerber et al. Nov 2015 B2
9220431 Holzhacker Dec 2015 B2
9220895 Siff et al. Dec 2015 B2
9227056 Heldman et al. Jan 2016 B1
9238137 Einav et al. Jan 2016 B2
9238142 Heldman et al. Jan 2016 B2
9242085 Hershey et al. Jan 2016 B2
9248285 Haessler Feb 2016 B2
9248286 Simon et al. Feb 2016 B2
9248297 Hoyer et al. Feb 2016 B2
9254382 Ahmad et al. Feb 2016 B2
9259577 Kaula et al. Feb 2016 B2
9265927 Yonce et al. Feb 2016 B2
9282928 Giffrida Mar 2016 B1
9289607 Su et al. Mar 2016 B2
9301712 McNames et al. Apr 2016 B2
9302046 Giuffrida et al. Apr 2016 B1
9311686 Roush et al. Apr 2016 B2
9314190 Giuffrida et al. Apr 2016 B1
9314622 Embrey et al. Apr 2016 B2
9332918 Buckley et al. May 2016 B1
9339213 Otsamo et al. May 2016 B2
9339641 Rajguru et al. May 2016 B2
9345872 Groteke May 2016 B2
9364657 Kiani et al. Jun 2016 B2
9364672 Marnfeldt Jun 2016 B2
9375570 Kiani et al. Jun 2016 B2
9387338 Burnett Jul 2016 B2
9393430 Demers et al. Jul 2016 B2
9408683 St. Anne et al. Aug 2016 B2
9414776 Sillay et al. Aug 2016 B2
9415205 Lasko et al. Aug 2016 B2
9452287 Rosenbluth et al. Sep 2016 B2
9468753 Fisher et al. Oct 2016 B2
9474898 Gozani et al. Oct 2016 B2
9549872 Chen et al. Jan 2017 B2
9581972 Arrow et al. Feb 2017 B1
9586038 Kosierkiewicz Mar 2017 B1
9589698 Anhalt et al. Mar 2017 B2
9597509 Hoffer et al. Mar 2017 B2
9610442 Yoo et al. Apr 2017 B2
9610459 Burnett et al. Apr 2017 B2
9615797 John Apr 2017 B2
9630004 Rajguru et al. Apr 2017 B2
9649486 Holzhacker May 2017 B2
9656070 Gozani et al. May 2017 B2
9669211 Wijting et al. Jun 2017 B2
9675800 Li et al. Jun 2017 B2
9675801 Kong et al. Jun 2017 B2
9707393 Hsueh et al. Jul 2017 B2
9731126 Ferree et al. Aug 2017 B2
9757584 Burnett Sep 2017 B2
9782584 Cartledge et al. Oct 2017 B2
9802041 Wong et al. Oct 2017 B2
9861283 Giuffrida Jan 2018 B1
9877679 Giuffrida Jan 2018 B1
9877680 Giuffrida et al. Jan 2018 B1
9884179 Bouton et al. Feb 2018 B2
9924899 Pracar et al. Mar 2018 B2
9956395 Bikson et al. May 2018 B2
9974478 Brokaw et al. May 2018 B1
9980659 Sadeghian-Motahar et al. May 2018 B2
9992918 Watanabe et al. Jun 2018 B2
10004900 Kent et al. Jun 2018 B2
10016600 Creasey et al. Jul 2018 B2
10022545 Giuffrida Jul 2018 B1
10028695 Machado et al. Jul 2018 B2
10045740 John Aug 2018 B2
10046161 Biasiucci et al. Aug 2018 B2
10076656 Dar et al. Sep 2018 B2
10080885 Nathan et al. Sep 2018 B2
10112040 Herb et al. Oct 2018 B2
10118035 Perez et al. Nov 2018 B2
10130809 Cartledge et al. Nov 2018 B2
10130810 Ferree et al. Nov 2018 B2
10137025 Fior et al. Nov 2018 B2
10173060 Wong et al. Jan 2019 B2
10179238 Wong et al. Jan 2019 B2
10213593 Kaplan et al. Feb 2019 B2
10213602 Ironi et al. Feb 2019 B2
10232174 Simon et al. Mar 2019 B2
10252053 Page et al. Apr 2019 B2
10285646 Grant May 2019 B1
10286210 Yoo May 2019 B2
10293159 Kong et al. May 2019 B2
10335594 Lin et al. Jul 2019 B2
10335595 Ferree et al. Jul 2019 B2
10342977 Raghunathan Jul 2019 B2
10398896 Lin et al. Sep 2019 B2
10456573 Feinstein et al. Oct 2019 B1
10463854 Perez Nov 2019 B2
10500396 Tamaki et al. Dec 2019 B2
10537732 Nachum et al. Jan 2020 B2
10549093 Wong et al. Feb 2020 B2
10556107 Yoo et al. Feb 2020 B2
10561839 Wong et al. Feb 2020 B2
10603482 Hamner et al. Mar 2020 B2
10610114 Buckley et al. Apr 2020 B2
10625074 Rosenbluth et al. Apr 2020 B2
10632312 Ziv Apr 2020 B2
10661082 Kerselaers May 2020 B2
10722709 Yoo et al. Jul 2020 B2
10765856 Wong et al. Sep 2020 B2
10773079 Keller et al. Sep 2020 B2
10780269 Gozani et al. Sep 2020 B2
10786669 Rajguru et al. Sep 2020 B2
10814130 Wong et al. Oct 2020 B2
10814131 Goldwasser et al. Oct 2020 B2
10835736 Horter et al. Nov 2020 B2
10850090 Rosenbluth et al. Dec 2020 B2
10870002 Wybo et al. Dec 2020 B2
10905879 Wong et al. Feb 2021 B2
10918853 Creasey et al. Feb 2021 B2
10940311 Gozani et al. Mar 2021 B2
10945879 Black et al. Mar 2021 B2
10960207 Wong et al. Mar 2021 B2
10967177 Lee Apr 2021 B2
11026835 Black et al. Jun 2021 B2
11033206 Roh Jun 2021 B2
11033731 Jeffery et al. Jun 2021 B2
11033736 Edgerton et al. Jun 2021 B2
11058867 Nathan et al. Jul 2021 B2
11077300 McBride Aug 2021 B2
11077301 Creasey et al. Aug 2021 B2
11103699 Oppenheim et al. Aug 2021 B1
11141586 Campean et al. Oct 2021 B2
11141587 Campean et al. Oct 2021 B2
11160971 Sharma et al. Nov 2021 B2
11213681 Raghunathan Jan 2022 B2
11224742 Burnett Jan 2022 B2
11247040 Ferree et al. Feb 2022 B2
11247053 Rajguru et al. Feb 2022 B2
11266836 Charlesworth et al. Mar 2022 B2
11318307 Kern et al. May 2022 B2
11331480 Hamner et al. May 2022 B2
11338120 Yun et al. May 2022 B2
11338128 Lawson et al. May 2022 B2
11344722 Wong et al. May 2022 B2
11357981 Moaddeb et al. Jun 2022 B2
11389651 Tamaki et al. Jul 2022 B2
11420052 Doskocil et al. Aug 2022 B2
11484710 Mantovani et al. Nov 2022 B2
11504530 Herr et al. Nov 2022 B2
11517753 Rhodes Dec 2022 B2
11534605 Bouton et al. Dec 2022 B2
11590348 Moaddeb et al. Feb 2023 B2
11596784 Hamner et al. Mar 2023 B1
11596791 Wong et al. Mar 2023 B2
11596792 Campean et al. Mar 2023 B2
11628300 Rajguru et al. Apr 2023 B2
11642513 Sharma et al. May 2023 B2
11672981 Jaasma et al. Jun 2023 B2
11766191 Sharma et al. Sep 2023 B2
11833352 Law et al. Dec 2023 B2
11839762 Doskocil et al. Dec 2023 B2
11844943 Rajguru et al. Dec 2023 B2
11857778 Hamner et al. Jan 2024 B2
11872399 Raghunathan Jan 2024 B2
11878166 Colburn et al. Jan 2024 B2
11890468 Yu Feb 2024 B1
11890469 Moaddeb et al. Feb 2024 B2
11896824 Doskocil Feb 2024 B2
11911604 Sharma et al. Feb 2024 B2
11918806 Wong et al. Mar 2024 B2
11975190 Cho et al. May 2024 B2
11992685 Kassiri Bidhendi et al. May 2024 B2
20010020177 Gruzdowich et al. Sep 2001 A1
20020055761 Mann et al. May 2002 A1
20020161415 Cohen et al. Oct 2002 A1
20020165586 Hill et al. Nov 2002 A1
20020177882 DiLorenzo Nov 2002 A1
20030032992 Thacker et al. Feb 2003 A1
20030045922 Northrop Mar 2003 A1
20030088294 Gesotti May 2003 A1
20030093098 Heitzmann et al. May 2003 A1
20030149457 Tcheng et al. Aug 2003 A1
20030181959 Dobak, III Sep 2003 A1
20030187483 Grey et al. Oct 2003 A1
20030195583 Gruzdowich et al. Oct 2003 A1
20040015094 Manabe et al. Jan 2004 A1
20040088025 Gessotti May 2004 A1
20040093093 Andrews May 2004 A1
20040102819 Zou et al. May 2004 A1
20040127939 Grey et al. Jul 2004 A1
20040133249 Gesotti Jul 2004 A1
20040167588 Bertolucci Aug 2004 A1
20040249416 Yun et al. Dec 2004 A1
20040267331 Koeneman et al. Dec 2004 A1
20050021103 DiLorenzo Jan 2005 A1
20050055063 Loeb et al. Mar 2005 A1
20050060009 Geotz Mar 2005 A1
20050065553 Ben Ezra et al. Mar 2005 A1
20050075502 Shafer Apr 2005 A1
20050171576 Williams et al. Aug 2005 A1
20050171577 Cohen et al. Aug 2005 A1
20050182454 Gharib et al. Aug 2005 A1
20050222626 DiLorenzo Oct 2005 A1
20050234309 Klapper Oct 2005 A1
20050240241 Yun et al. Oct 2005 A1
20060015153 Gliner et al. Jan 2006 A1
20060047326 Wheeler Mar 2006 A1
20060052726 Weisz et al. Mar 2006 A1
20060074450 Boveja et al. Apr 2006 A1
20060095088 De Ridder May 2006 A1
20060161218 Danilov Jul 2006 A1
20060173509 Lee et al. Aug 2006 A1
20060184059 Jadidi Aug 2006 A1
20060217781 John Sep 2006 A1
20060224191 DiLorenzo Oct 2006 A1
20060229678 Lee Oct 2006 A1
20060253167 Kurtz et al. Nov 2006 A1
20060276853 Tass Dec 2006 A1
20060293723 Whitehurst et al. Dec 2006 A1
20070027486 Armstrong Feb 2007 A1
20070073361 Goren et al. Mar 2007 A1
20070123951 Boston May 2007 A1
20070123952 Strother et al. May 2007 A1
20070142862 DiLorenzo Jun 2007 A1
20070156179 Karashurov Jul 2007 A1
20070156182 Castel et al. Jul 2007 A1
20070156183 Rhodes Jul 2007 A1
20070156200 Kornet et al. Jul 2007 A1
20070173899 Levin et al. Jul 2007 A1
20070173903 Goren et al. Jul 2007 A1
20070203533 Goren et al. Aug 2007 A1
20070203534 Tapper Aug 2007 A1
20070207193 Zasler et al. Sep 2007 A1
20070249952 Rubin et al. Oct 2007 A1
20070255319 Greenberg Nov 2007 A1
20070276217 Brown et al. Nov 2007 A1
20070282228 Einav et al. Dec 2007 A1
20080004672 Dalal et al. Jan 2008 A1
20080009772 Tyler et al. Jan 2008 A1
20080021505 Hastings et al. Jan 2008 A1
20080027507 Bijelic et al. Jan 2008 A1
20080030170 Dacuay et al. Feb 2008 A1
20080033259 Manto et al. Feb 2008 A1
20080033504 Bertolucci Feb 2008 A1
20080051839 Libbus et al. Feb 2008 A1
20080051845 Mentelos Feb 2008 A1
20080058773 John Mar 2008 A1
20080058871 Libbus et al. Mar 2008 A1
20080058893 Noujokat Mar 2008 A1
20080097564 Lathrop Apr 2008 A1
20080147146 Wahlgren et al. Jun 2008 A1
20080177398 Gross et al. Jul 2008 A1
20080195007 Podrazhansky et al. Aug 2008 A1
20080208282 Gelfand et al. Aug 2008 A1
20080208288 Podrazhansky et al. Aug 2008 A1
20080216593 Jacobsen et al. Sep 2008 A1
20080243204 Uthman et al. Oct 2008 A1
20080288016 Amurthur et al. Nov 2008 A1
20080300449 Gerber et al. Dec 2008 A1
20080306325 Burnett et al. Dec 2008 A1
20080312520 Rowlandson et al. Dec 2008 A1
20090018609 DiLorenzo Jan 2009 A1
20090076565 Surwit Mar 2009 A1
20090082831 Paul et al. Mar 2009 A1
20090099623 Bentwich Apr 2009 A1
20090105785 Wei et al. Apr 2009 A1
20090112133 Deisseroth et al. Apr 2009 A1
20090157138 Errico et al. Jun 2009 A1
20090187121 Evans Jul 2009 A1
20090216294 Ewing et al. Aug 2009 A1
20090222053 Gaunt et al. Sep 2009 A1
20090247910 Klapper Oct 2009 A1
20090249617 Karicherla et al. Oct 2009 A1
20090299435 Gliner et al. Dec 2009 A1
20090312690 Kim et al. Dec 2009 A1
20090318986 Alo et al. Dec 2009 A1
20090326595 Brockway et al. Dec 2009 A1
20090326607 Castel et al. Dec 2009 A1
20100004715 Fahey Jan 2010 A1
20100010381 Skelton et al. Jan 2010 A1
20100010383 Skelton et al. Jan 2010 A1
20100010572 Skelton et al. Jan 2010 A1
20100057154 Dietrich et al. Mar 2010 A1
20100059722 Copp-Howland et al. Mar 2010 A1
20100076533 Dar et al. Mar 2010 A1
20100099963 Kilger Apr 2010 A1
20100107657 Vistakula May 2010 A1
20100125220 Seong May 2010 A1
20100152817 Gillbe Jun 2010 A1
20100168501 Burnett et al. Jul 2010 A1
20100168604 Echauz Jul 2010 A1
20100174342 Boston et al. Jul 2010 A1
20100222630 Mangrum et al. Sep 2010 A1
20100227330 Fink et al. Sep 2010 A1
20100228180 Jayes et al. Sep 2010 A1
20100249637 Walter et al. Sep 2010 A1
20100292527 Schneider et al. Nov 2010 A1
20100298905 Simon Nov 2010 A1
20100324611 Deming et al. Dec 2010 A1
20110004268 Tcheng et al. Jan 2011 A1
20110009920 Whitehurst et al. Jan 2011 A1
20110021899 Arps et al. Jan 2011 A1
20110040204 Ivorra et al. Feb 2011 A1
20110040288 Eckstein et al. Feb 2011 A1
20110054358 Kim et al. Mar 2011 A1
20110071590 Mounaim et al. Mar 2011 A1
20110098780 Graupe et al. Apr 2011 A1
20110112605 Fahey May 2011 A1
20110118805 Wei et al. May 2011 A1
20110125212 Tyler May 2011 A1
20110137375 McBride Jun 2011 A1
20110184489 Nicolelis et al. Jul 2011 A1
20110196446 Wu Aug 2011 A1
20110202107 Sunagawa et al. Aug 2011 A1
20110208444 Solinky Aug 2011 A1
20110213278 Horak et al. Sep 2011 A1
20110224571 Pascual-Leone et al. Sep 2011 A1
20110230701 Simon et al. Sep 2011 A1
20110245734 Wagner et al. Oct 2011 A1
20110250297 Oronsky et al. Oct 2011 A1
20110282412 Glukhovsky et al. Nov 2011 A1
20110288615 Armstrong et al. Nov 2011 A1
20110301663 Wang et al. Dec 2011 A1
20120010492 Thramann et al. Jan 2012 A1
20120046535 Lin et al. Feb 2012 A1
20120050298 Hoffman Mar 2012 A1
20120053491 Nathan et al. Mar 2012 A1
20120059298 Hoffman et al. Mar 2012 A1
20120078319 De Ridder Mar 2012 A1
20120088986 David et al. Apr 2012 A1
20120092178 Callsen et al. Apr 2012 A1
20120098493 Budike Apr 2012 A1
20120101326 Simon et al. Apr 2012 A1
20120109013 Everett et al. May 2012 A1
20120136410 Rezai et al. May 2012 A1
20120158094 Kramer et al. Jun 2012 A1
20120184801 Simon et al. Jul 2012 A1
20120185020 Simon et al. Jul 2012 A1
20120211013 Otis Aug 2012 A1
20120220812 Mishelevich Aug 2012 A1
20120239112 Muraoka Sep 2012 A1
20120245483 Lundqvist Sep 2012 A1
20120259255 Tomlinson et al. Oct 2012 A1
20120277621 Gerber et al. Nov 2012 A1
20120289869 Tyler Nov 2012 A1
20120290036 Karamanoglu et al. Nov 2012 A1
20120302821 Burnett Nov 2012 A1
20120310298 Besio et al. Dec 2012 A1
20120310299 Norbert et al. Dec 2012 A1
20120310303 Popovic et al. Dec 2012 A1
20120330182 Alberts et al. Dec 2012 A1
20130006322 Tai Jan 2013 A1
20130035745 Ahmed et al. Feb 2013 A1
20130053817 Yun et al. Feb 2013 A1
20130060124 Zietsma Mar 2013 A1
20130066388 Bernhard et al. Mar 2013 A1
20130066395 Simon et al. Mar 2013 A1
20130085317 Feinstein Apr 2013 A1
20130090519 Tass Apr 2013 A1
20130106684 Weast et al. May 2013 A1
20130116606 Cordo May 2013 A1
20130123568 Hamilton et al. May 2013 A1
20130123666 Giuffrida et al. May 2013 A1
20130131484 Pernu May 2013 A1
20130131770 Rezai May 2013 A1
20130158624 Bain et al. Jun 2013 A1
20130158627 Gozani et al. Jun 2013 A1
20130178765 Mishelevich Jul 2013 A1
20130211471 Libbus et al. Aug 2013 A1
20130231713 De Ridder et al. Sep 2013 A1
20130236867 Avni et al. Sep 2013 A1
20130238049 Simon et al. Sep 2013 A1
20130245486 Simon et al. Sep 2013 A1
20130245713 Tass Sep 2013 A1
20130253299 Weber et al. Sep 2013 A1
20130267759 Jin Oct 2013 A1
20130281890 Mishelevich Oct 2013 A1
20130289647 Bhadra et al. Oct 2013 A1
20130296967 Skaribas et al. Nov 2013 A1
20130297022 Pathak Nov 2013 A1
20130331907 Sumners et al. Dec 2013 A1
20130333094 Rogers et al. Dec 2013 A1
20130338726 Machado Dec 2013 A1
20140025059 Kerr Jan 2014 A1
20140031605 Schneider Jan 2014 A1
20140039573 Jindra Feb 2014 A1
20140039575 Bradley Feb 2014 A1
20140046423 Rajguru et al. Feb 2014 A1
20140058189 Stubbeman Feb 2014 A1
20140067003 Vase et al. Mar 2014 A1
20140078694 Wissmar Mar 2014 A1
20140081345 Hershey Mar 2014 A1
20140094675 Luna et al. Apr 2014 A1
20140094873 Emborg et al. Apr 2014 A1
20140128939 Embrey et al. May 2014 A1
20140132410 Chang May 2014 A1
20140142654 Simon et al. May 2014 A1
20140148872 Goldwasser et al. May 2014 A1
20140148873 Kirn May 2014 A1
20140163444 Ingvarsson Jun 2014 A1
20140171834 DeGoede et al. Jun 2014 A1
20140200573 Deem et al. Jul 2014 A1
20140214119 Greiner et al. Jul 2014 A1
20140228927 Ahmad et al. Aug 2014 A1
20140236258 Carroll et al. Aug 2014 A1
20140246628 Anhalt et al. Sep 2014 A1
20140249452 Marsh et al. Sep 2014 A1
20140257047 Slliay et al. Sep 2014 A1
20140257129 Choi et al. Sep 2014 A1
20140276194 Osorio Sep 2014 A1
20140277220 Brennan et al. Sep 2014 A1
20140296752 Edgerton et al. Oct 2014 A1
20140296934 Gozani et al. Oct 2014 A1
20140296935 Ferree Oct 2014 A1
20140300490 Kotz et al. Oct 2014 A1
20140309709 Gozanl et al. Oct 2014 A1
20140316484 Edgerton et al. Oct 2014 A1
20140324118 Simon et al. Oct 2014 A1
20140330068 Partsch et al. Nov 2014 A1
20140330335 Errico et al. Nov 2014 A1
20140336003 Franz et al. Nov 2014 A1
20140336722 Rocon De Lima et al. Nov 2014 A1
20140343462 Burnet Nov 2014 A1
20140350436 Nathan et al. Nov 2014 A1
20140358040 Kim et al. Dec 2014 A1
20140364678 Harry et al. Dec 2014 A1
20150004656 Tang et al. Jan 2015 A1
20150005852 Hershey et al. Jan 2015 A1
20150012067 Bradley et al. Jan 2015 A1
20150038886 Snow Feb 2015 A1
20150042315 Cen Feb 2015 A1
20150044656 Eichhorn et al. Feb 2015 A1
20150057506 Luna et al. Feb 2015 A1
20150073310 Pracar et al. Mar 2015 A1
20150080979 Lasko et al. Mar 2015 A1
20150100004 Goldman et al. Apr 2015 A1
20150100104 Kiani et al. Apr 2015 A1
20150100105 Kiani et al. Apr 2015 A1
20150148866 Bulsen et al. May 2015 A1
20150148878 Yoo et al. May 2015 A1
20150157274 Ghassemzadeh et al. Jun 2015 A1
20150164377 Nathan et al. Jun 2015 A1
20150164401 Toth et al. Jun 2015 A1
20150190085 Nathan et al. Jul 2015 A1
20150190634 Rezai et al. Jul 2015 A1
20150196767 Zaghloul Jul 2015 A1
20150202444 Franke et al. Jul 2015 A1
20150208955 Smith Jul 2015 A1
20150216475 Luna et al. Aug 2015 A1
20150230733 Heo et al. Aug 2015 A1
20150230756 Luna et al. Aug 2015 A1
20150277559 Vescovi et al. Oct 2015 A1
20150297901 Kockx Oct 2015 A1
20150321000 Rosenbluth et al. Nov 2015 A1
20150335882 Gross et al. Nov 2015 A1
20160001096 Mishelevich Jan 2016 A1
20160008620 Stubbeman Jan 2016 A1
20160016014 Wagner et al. Jan 2016 A1
20160022987 Zschaeck et al. Jan 2016 A1
20160022989 Pfeifer Jan 2016 A1
20160038059 Asada et al. Feb 2016 A1
20160045140 Kitamura et al. Feb 2016 A1
20160089045 Sadeghian-Motahar et al. Mar 2016 A1
20160106344 Nazari Apr 2016 A1
20160120432 Sridhar et al. May 2016 A1
20160121110 Kent et al. May 2016 A1
20160128621 Machado et al. May 2016 A1
20160129248 Creasey et al. May 2016 A1
20160158542 Ahmed Jun 2016 A1
20160158565 Lee Jun 2016 A1
20160198998 Rahimi et al. Jul 2016 A1
20160213924 Coleman et al. Jul 2016 A1
20160220836 Parks Aug 2016 A1
20160262685 Wagner et al. Sep 2016 A1
20160263376 Yoo et al. Sep 2016 A1
20160279435 Hyde et al. Sep 2016 A1
20160287879 Denison et al. Oct 2016 A1
20160039239 Yoo et al. Nov 2016 A1
20160336722 Taxter Nov 2016 A1
20160339239 Yoo et al. Nov 2016 A1
20160361540 Simon et al. Dec 2016 A9
20160375249 Bonnet et al. Dec 2016 A1
20170014625 Rosenbluth et al. Jan 2017 A1
20170027812 Hyde et al. Feb 2017 A1
20170042467 Herr et al. Feb 2017 A1
20170056238 Yi et al. Mar 2017 A1
20170056643 Herb et al. Mar 2017 A1
20170079597 Horne Mar 2017 A1
20170080207 Perez et al. Mar 2017 A1
20170095667 Yakovlev Apr 2017 A1
20170113045 Baldassano et al. Apr 2017 A1
20170157398 Wong et al. Jun 2017 A1
20170165485 Sullivan et al. Jun 2017 A1
20170132067 Wong et al. Aug 2017 A1
20170224991 Wingeier Aug 2017 A1
20170239415 Hwang et al. Aug 2017 A1
20170246481 Mishelevich Aug 2017 A1
20170266443 Rajguru et al. Sep 2017 A1
20170274208 Nagel et al. Sep 2017 A1
20170287146 Pathak et al. Oct 2017 A1
20170312505 Ahmed Nov 2017 A1
20170312512 Creasey et al. Nov 2017 A1
20170312513 Hershey et al. Nov 2017 A1
20170361093 Yoo et al. Dec 2017 A1
20170368329 Tyler et al. Dec 2017 A1
20180001086 Bartholomew et al. Jan 2018 A1
20180001088 Tass Jan 2018 A1
20180021576 Wong et al. Jan 2018 A1
20180028841 Konofagou et al. Feb 2018 A1
20180036535 Wong et al. Feb 2018 A1
20180042654 Ingvarsson et al. Feb 2018 A1
20180049676 Griffiths et al. Feb 2018 A1
20180064344 Nguyen Mar 2018 A1
20180064362 Hennings et al. Mar 2018 A1
20180064944 Grill et al. Mar 2018 A1
20180116546 Pastoor et al. May 2018 A1
20180132757 Kong et al. May 2018 A1
20180140842 Olaighin et al. May 2018 A1
20180168905 Goodall et al. Jun 2018 A1
20180169400 Wong et al. Jun 2018 A1
20180214694 Parramon Aug 2018 A1
20180221620 Metzger Aug 2018 A1
20180235500 Lee et al. Aug 2018 A1
20180236217 Hamner et al. Aug 2018 A1
20180264263 Rosenbluth et al. Sep 2018 A1
20180345020 Ironi et al. Dec 2018 A1
20190001117 Ben-David et al. Jan 2019 A1
20190001129 Rosenbluth et al. Jan 2019 A1
20190001139 Mishra et al. Jan 2019 A1
20190126047 Kassiri Bidhendi et al. May 2019 A1
20190143098 Kaplan et al. May 2019 A1
20190143111 Hamner et al. May 2019 A1
20190143113 Wong et al. May 2019 A1
20190167976 Byers et al. Jun 2019 A1
20190269914 Moaddeb et al. Sep 2019 A1
20190298998 Coleman et al. Oct 2019 A1
20190321636 Law et al. Oct 2019 A1
20190343462 Grant Nov 2019 A1
20190374771 Simon et al. Dec 2019 A1
20200023183 Ollerenshaw et al. Jan 2020 A1
20200038654 Doskocil et al. Feb 2020 A1
20200046968 Herr et al. Feb 2020 A1
20200061378 Ganguly et al. Feb 2020 A1
20200093400 Hamner et al. Mar 2020 A1
20200139118 John et al. May 2020 A1
20200147373 Tamaki et al. May 2020 A1
20200155847 Perez May 2020 A1
20200171269 Hooper et al. Jun 2020 A1
20200171304 Simon et al. Jun 2020 A1
20200179687 Wong et al. Jun 2020 A1
20200197707 Covalin Jun 2020 A1
20200215324 Mantovani et al. Jul 2020 A1
20200221975 Basta et al. Jul 2020 A1
20200254247 Brezel et al. Aug 2020 A1
20200254251 Wong et al. Aug 2020 A1
20200269046 Page et al. Aug 2020 A1
20200276442 Owen Sep 2020 A1
20200282201 Doskocil Sep 2020 A1
20200289813 Ito et al. Sep 2020 A1
20200289814 Hamner et al. Sep 2020 A1
20200297999 Pal Sep 2020 A1
20200316379 Yoo et al. Oct 2020 A1
20200324104 Labuschagne et al. Oct 2020 A1
20200338348 Honeycutt et al. Oct 2020 A1
20200367775 Buckley et al. Nov 2020 A1
20200405188 Sharma et al. Dec 2020 A1
20200406022 Sharma et al. Dec 2020 A1
20210016079 Ekelem et al. Jan 2021 A1
20210031026 Simon et al. Feb 2021 A1
20210031036 Sharma et al. Feb 2021 A1
20210052883 Wong et al. Feb 2021 A1
20210052897 Bhadra et al. Feb 2021 A1
20210052900 Pepin et al. Feb 2021 A1
20210060337 Wybo et al. Mar 2021 A1
20210069507 Gozani et al. Mar 2021 A1
20210100999 Rosenbluth et al. Apr 2021 A1
20210101007 Hamner et al. Apr 2021 A1
20210113834 Wong et al. Apr 2021 A1
20210162212 Kern et al. Jun 2021 A1
20210169684 Black et al. Jun 2021 A1
20210187279 Bouton et al. Jun 2021 A1
20210205619 Wong et al. Jul 2021 A1
20210213283 Yoo et al. Jul 2021 A1
20210220650 Kassiri Bidhendi et al. Jul 2021 A1
20210244940 Liberatore et al. Aug 2021 A1
20210244950 Ironi et al. Aug 2021 A1
20210252278 Hamner et al. Aug 2021 A1
20210260379 Charlesworth et al. Aug 2021 A1
20210266011 Chen et al. Aug 2021 A1
20210283400 Hamner et al. Sep 2021 A1
20210289814 Roubos-van den Hil et al. Sep 2021 A1
20210299445 Rajguru et al. Sep 2021 A1
20210308460 Wong et al. Oct 2021 A1
20210330547 Moaddeb et al. Oct 2021 A1
20210330974 Wong et al. Oct 2021 A1
20210353181 Roh Nov 2021 A1
20210379374 Hamner et al. Dec 2021 A1
20210379379 Campean et al. Dec 2021 A1
20210402172 Ross et al. Dec 2021 A1
20220001164 Sharma et al. Jan 2022 A1
20220016413 John et al. Jan 2022 A1
20220031245 Bresler Feb 2022 A1
20220054820 Turner Feb 2022 A1
20220054831 McBride Feb 2022 A1
20220088373 Burnett Mar 2022 A1
20220126095 Rajguru et al. Apr 2022 A1
20220143391 Vaishya et al. May 2022 A1
20220143392 Labuschagne et al. May 2022 A1
20220143393 Charlesworth et al. May 2022 A1
20220143402 Oppenheim et al. May 2022 A1
20220203091 Vysokov Jun 2022 A1
20220212007 Rajguru et al. Jul 2022 A1
20220218991 Moaddeb et al. Jul 2022 A1
20220220276 Ziebell et al. Jul 2022 A1
20220233860 Hamner et al. Jul 2022 A1
20220266011 Hamner et al. Aug 2022 A1
20220266012 Hamner et al. Aug 2022 A1
20220347461 Campean et al. Nov 2022 A1
20220401721 Jackson et al. Dec 2022 A1
20230009158 Liberatore Jan 2023 A1
20230010696 Pradeep Jan 2023 A1
20230062326 Colachis et al. Mar 2023 A1
20230110185 Mantovani et al. Apr 2023 A1
20230191115 Blum et al. Jun 2023 A1
20230191126 Kent et al. Jun 2023 A1
20230201584 Rajguru et al. Jun 2023 A1
20230218897 Wang et al. Jul 2023 A1
20230248962 Zhang et al. Aug 2023 A1
20230277109 Blum et al. Sep 2023 A1
20230277841 Wang et al. Sep 2023 A1
20230285743 Muccio Sep 2023 A1
20230293882 Howe Sep 2023 A1
20230321430 Ye et al. Oct 2023 A1
20230371846 Sharma et al. Nov 2023 A1
20240058606 Law et al. Feb 2024 A1
20240066286 Yin et al. Feb 2024 A1
20240066287 Siff Feb 2024 A1
20240090600 Colachis et al. Mar 2024 A1
20240122797 Moaddeb et al. Apr 2024 A1
20240123230 Raghunathan Apr 2024 A1
20240157142 Yeniel et al. May 2024 A1
20240189594 Hamner et al. Jun 2024 A1
20240325727 Hamner et al. Oct 2024 A1
20240325728 Schulte et al. Oct 2024 A1
Foreign Referenced Citations (218)
Number Date Country
1135722 Nov 1996 CN
1547483 Nov 2004 CN
1826154 Aug 2006 CN
101022849 Aug 2007 CN
101115524 Jan 2008 CN
101365373 Feb 2009 CN
101687093 Mar 2010 CN
101801453 Aug 2010 CN
102089031 Jun 2011 CN
102481394 May 2012 CN
202724457 Feb 2013 CN
103517732 Jan 2014 CN
103889503 Jun 2014 CN
104144729 Nov 2014 CN
104168951 Nov 2014 CN
104519960 Apr 2015 CN
105457158 Apr 2016 CN
105848710 Aug 2016 CN
106413805 Feb 2017 CN
106687161 May 2017 CN
106794347 May 2017 CN
107949421 Apr 2018 CN
108697890 Oct 2018 CN
102008042373 Apr 2010 DE
102009004011 Jul 2010 DE
0 000 759 Feb 1979 EP
0 725 665 Jan 1998 EP
1 062 988 Dec 2000 EP
1 558 333 May 2007 EP
1 727 591 Apr 2009 EP
2 383 014 Nov 2011 EP
2 291 115 Sep 2013 EP
2 801 389 Nov 2014 EP
3 020 448 May 2016 EP
2 029 222 Mar 2017 EP
2 780 073 Sep 2017 EP
1 951 365 Oct 2017 EP
3 154 627 Apr 2018 EP
2 827 771 May 2018 EP
3 184 143 Jul 2018 EP
3 075 412 Dec 2018 EP
3 349 712 Jul 2019 EP
3 503 960 Mar 2020 EP
3 352 846 Jul 2020 EP
3 493 874 Aug 2020 EP
3 409 200 Sep 2020 EP
3 427 793 Nov 2020 EP
3758595 Jan 2021 EP
3 641 876 Apr 2021 EP
3 679 979 Jun 2021 EP
3 402 404 Jul 2021 EP
3 562 541 Jul 2021 EP
3 675 795 Aug 2021 EP
3 100 765 Jan 2022 EP
3487578 Dec 2022 EP
4108292 Dec 2022 EP
3784337 Jun 2023 EP
4233990 Aug 2023 EP
3541279 Sep 2023 EP
3463550 Mar 2024 EP
3565631 Apr 2024 EP
4356952 Apr 2024 EP
3842094 May 2024 EP
2222819 Mar 2006 ES
2272137 Jun 2008 ES
2496449 May 2013 GB
2002-200178 Jul 2002 JP
2003-501207 Jan 2003 JP
2003-533299 Nov 2003 JP
2004-512104 Apr 2004 JP
2006-503658 Feb 2006 JP
2008-018235 Jan 2008 JP
2009-034328 Feb 2009 JP
2009-512516 Mar 2009 JP
2009-529352 Aug 2009 JP
2010-506618 Mar 2010 JP
2010-512926 Apr 2010 JP
2010-246745 Nov 2010 JP
2012-005596 Jan 2012 JP
2012-055650 Mar 2012 JP
2012-217565 Nov 2012 JP
2013-017609 Jan 2013 JP
2013-094305 May 2013 JP
5439921 Mar 2014 JP
2015-514460 May 2015 JP
2016-511651 Apr 2016 JP
2018-038597 Mar 2018 JP
20130104446 Sep 2013 KR
WO 8701024 Feb 1987 WO
WO 94000187 Jan 1994 WO
WO 94017855 Aug 1994 WO
WO 96032909 Oct 1996 WO
WO 98043700 Oct 1998 WO
WO 99019019 Apr 1999 WO
WO 00015293 Mar 2000 WO
WO 00076436 Dec 2000 WO
WO 01087411 Nov 2001 WO
WO 02017987 Mar 2002 WO
WO 0234327 May 2002 WO
WO 2004037344 May 2004 WO
WO 2004108209 Dec 2004 WO
WO 2005007029 May 2005 WO
WO 05122894 Dec 2005 WO
WO 2006021820 Mar 2006 WO
WO 2006092007 Sep 2006 WO
WO 2006102724 Oct 2006 WO
WO 07092290 Aug 2007 WO
WO 2007092290 Aug 2007 WO
WO 07112092 Oct 2007 WO
WO 08045598 Apr 2008 WO
WO 08062395 May 2008 WO
WO 2008106174 Sep 2008 WO
WO 09153730 Dec 2009 WO
WO 2010014260 Feb 2010 WO
WO 10111321 Sep 2010 WO
WO 10141155 Dec 2010 WO
WO 11119224 Sep 2011 WO
WO 2011144883 Nov 2011 WO
WO 2011149656 Dec 2011 WO
WO 12040243 Mar 2012 WO
WO 13071307 May 2013 WO
WO 13074809 May 2013 WO
WO 13173727 Nov 2013 WO
WO 14043757 Mar 2014 WO
WO 14053041 Apr 2014 WO
WO 2014070999 May 2014 WO
WO 14089549 Jun 2014 WO
WO 14093964 Jun 2014 WO
WO 2014113813 Jul 2014 WO
WO 14146082 Sep 2014 WO
WO 14151431 Sep 2014 WO
WO 14153201 Sep 2014 WO
WO 14207512 Dec 2014 WO
WO 15033152 Mar 2015 WO
WO 15039206 Mar 2015 WO
WO 15039244 Mar 2015 WO
WO 15042365 Mar 2015 WO
WO 15079319 Jun 2015 WO
WO 15095880 Jun 2015 WO
WO 2015085880 Jun 2015 WO
WO 15128090 Sep 2015 WO
WO 15138981 Sep 2015 WO
WO 2015138981 Sep 2015 WO
WO 15164706 Oct 2015 WO
WO 2015187712 Dec 2015 WO
WO 16007093 Jan 2016 WO
WO 16019250 Feb 2016 WO
WO 16094728 Jun 2016 WO
WO 16102958 Jun 2016 WO
WO 16110804 Jul 2016 WO
WO 16128985 Aug 2016 WO
WO 16149751 Sep 2016 WO
WO 16166281 Oct 2016 WO
WO 16179407 Nov 2016 WO
WO 2016176668 Nov 2016 WO
WO 16189422 Dec 2016 WO
WO 16195587 Dec 2016 WO
WO 2016201366 Dec 2016 WO
WO 17004021 Jan 2017 WO
WO 17010930 Jan 2017 WO
WO 2017023864 Feb 2017 WO
WO 17044904 Mar 2017 WO
WO 2017053847 Mar 2017 WO
WO 17062994 Apr 2017 WO
WO 17086798 May 2017 WO
WO 17088573 Jun 2017 WO
WO 2017132067 Aug 2017 WO
WO 17199026 Nov 2017 WO
WO 17208167 Dec 2017 WO
WO 17209673 Dec 2017 WO
WO 17210729 Dec 2017 WO
WO 17221037 Dec 2017 WO
WO 2018009680 Jan 2018 WO
WO 18028170 Feb 2018 WO
WO 18028220 Feb 2018 WO
WO 18028221 Feb 2018 WO
WO 2018039458 Mar 2018 WO
WO 18093765 May 2018 WO
WO 18106839 Jun 2018 WO
WO 18112164 Jun 2018 WO
WO 2018106839 Jun 2018 WO
WO 2018119220 Jun 2018 WO
WO 2018187241 Oct 2018 WO
WO 19005774 Jan 2019 WO
WO 19014250 Jan 2019 WO
WO 19028000 Feb 2019 WO
WO 19046180 Mar 2019 WO
WO 19082180 Jun 2019 WO
WO 2019143790 Jul 2019 WO
WO 19169240 Sep 2019 WO
WO 19202489 Oct 2019 WO
WO 2019213433 Nov 2019 WO
WO 2020006048 Jan 2020 WO
WO 20068830 Apr 2020 WO
WO 2020069219 Apr 2020 WO
WO 2020086726 Apr 2020 WO
WO 20131857 Jun 2020 WO
WO 20185601 Sep 2020 WO
WO 21005584 Jan 2021 WO
WO 21055716 Mar 2021 WO
WO 21062345 Apr 2021 WO
WO 21127422 Jun 2021 WO
WO 21228128 Nov 2021 WO
WO 2021236815 Nov 2021 WO
WO 21252292 Dec 2021 WO
WO 2022090834 May 2022 WO
WO 2022221858 Oct 2022 WO
WO 2022235607 Nov 2022 WO
WO 2023283568 Jan 2023 WO
WO 2023014499 Feb 2023 WO
WO 2023015158 Feb 2023 WO
WO 2023015159 Mar 2023 WO
WO 2023156391 Aug 2023 WO
WO 2023163300 Aug 2023 WO
WO 2023191236 Oct 2023 WO
WO 2023196578 Oct 2023 WO
WO 2023222911 Nov 2023 WO
WO 2024083685 Apr 2024 WO
Non-Patent Literature Citations (152)
Entry
Apartis; Clinical neurophysiology in movement disorders. Handb Clin Neurol; 111; Pediatric Neurology Pt. 1; pp. 87-92;Apr. 2013.
Barath et al., 2020, Brain metabolic changes with longitudinal transcutaneous afferent patterned stimulation in essential tremor subjects, Tremor and Other Hyperkinetic Movements, 10(1):52, pp. 1-10.
Barbaud et al.; Improvement in essential tremor after pure sensory stroke due to thalamic infarction; European neurology; 46; pp. 57-59; Jul. 2001.
Barrios et al.: BCI algorithms for tremor identification, characterization and tracking; Seventh Framework Programme, EU; Contract No. FP7-ICT-2007-224051 (v3.0); 57 pgs.; Jul. 10, 2011.
Bartley et al.; Neuromodulation for overactive bladder; Nature Reviews Urology; 10; pp. 513-521; Sep. 2013.
Benabid et al.; A putative generalized model of the effects and mechanism of action of high frequency electrical stimulation of the central nervous system; Acta Neural Belg; 105(3); pp. 149-157; Sep. 2005.
Bergquist et al.: Motor unit recruitment when neuromuscular electrical stimulation is applied over a nerve trunk compared with a muscle belly: quadriceps femoris, Journal of Applied Physiology; vol. 113, No. 1, pp. 78-89; Jul. 2012.
Bergquist et al.; Motor unit recruitment when neuromuscular electrical stimulation is applied over a nerve trunk compared with a muscle belly: triceps surae, Journal of Applied Physiology; vol. 110, No. 3, pp. 627-637; Mar. 2011.
Bijelic et al.: E Actitrode®: The New Selective Stimulation Interface for Functional Movements in Hemiplegic Patients; Serbian Journal of Electrical Engineering; 1(3); pp. 21-28; Nov. 2004.
Birdno et al.; Pulse-to-pulse changes in the frequency of deep brain stimulation affect tremor and modeled neuronal activity.; Journal of Neurophysiology; 98; pp. 1675-1684; Jul. 2007.
Birdno et al.; Response of human thalamic neurons to high-frequency stimulation.; PloS One; 9(5); 10 pgs.; May 2014.
Birgersson et al.; Non-invasive bioimpedance of intact skin: mathematical modeling and experiments; Physiological Measurement; 32(1); pp. 1-18; Jan. 2011.
Bohling et al.; Comparison of the stratum corneum thickness measured in vivo with confocal Raman spectroscopy and confocal reflectance microscopy; Skin research and Technology; 20(1); pp. 50-47; Feb. 2014.
Bonaz, B., V. Sinniger, and S. Pellissier. “Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease.” Journal of internal medicine 282.1 (2017): 46-63.
Bowman et al.; Effects of waveform parameters on comfort during transcutaneous neuromuscular electrical stimulation; Annals of Biomedical Engineering; 13(1); pp. 59-74; Jan. 1985.
Bratton et al.; Neural regulation of inflammation: no neural connection from the vagus to splenic sympathetic neurons; Exp Physiol 97.11 (2012); pp. 1180-1185.
Brillman et al., 2022, Real-world evidence of transcutaneous afferent patterned stimulation for essential tremor, Tremor and Other Hyperkinetic Movements, 12(1):27, pp. 1-11.
Brittain et al.; Tremor suppression by rhythmic transcranial current stimulation; Current Biology; 23; pp. 436-440; Mar. 2013.
Britton et al.; Modulation of postural tremors at the wrist by supramaximal electrical median nerve shocks in ET, PD, and normal subjects mimicking tremor; J Neurology, Neurosurgery, and Psychiatry; 56(10); pp. 1085-1089; Oct. 1993.
Buschbacher et al.; Manual of nerve conduction series; 2nd edition; Demos Medical Publishing, LLC; 2006.
Cagnan et al.; Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation; Brain; 136(10); pp. 3062-3075; Oct. 2013.
Campero et al.; Peripheral projections of sensory fasicles in the human superificial radial nerve; Brain; 128(Pt 4); pp. 892-895; Apr. 2005.
Chen et al.; A web-based system for home monitoring of patients with Parkinson's disease using wearable sensors; IEEE Trans on Bio-Medical Engineering; 58(3); pp. 831-836; Mar. 2011.
Choi, Jong Bo, et al. “Analysis of heart rate variability in female patients with overactive bladder.” Urology 65.6 (2005): 1109-1112.
Clair et al.; Postactivation depression and recovery of reflex transmission during repetitive electrical stimulation of the human tibial nerve, Journal of Neurophysiology; vol. 106, No. 1; pp. 184-192; Jul. 2011.
Clar et al.; Skin impedance and moisturization; J. Soc. Cosmet. Chem.; 26; pp. 337-353; 1975; presented at IFSCC Vilith Int'l Congresson Cosmetics Quality and Safety in London on Aug. 26-30, 1974.
Constandinou et al.; A Partial-Current-Steering Biphasic Stimulation Driver for Vestibular Prostheses; IEEE Trans on Biomedical Circuits and Systems; 2(2); pp. 106-113; Jun. 2008.
Daneault et al.; Using a smart phone as a standalone platform for detection and monitoring of pathological tremors; Frontiers in Human Neuroscience; vol. 6, article 357; 12 pgs.; Jan. 2012.
Deuschl et at; Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee., Movement Disorders, vol. 13 Suppl 3, pp. 2-23; 1998.
Di Giovangiulio et al.; The Neuromodulation of the intestinal immune system and its relevance in inflammatory bowel disease; Fronteir's in Immunology; vol. 6; Article 590; Nov. 2015.
Dideriksen et al.; EMG-based characterization of pathological tremor using the iterated Hilbert transform; IEEE transactions on Bio-medical Engineering; 58(10); pp. 2911-2921; Oct. 2011.
Dosen et al.: Tremor suppression using electromyography and surface sensory electrical stimulation; Converging Clinical and Engineering Research on Neurorehabilitation; vol. 1 (Siosystems & Biorobotics Series); pp. 539-543; Feb. 2013.
Doucet et al.; Neuromuscular electrical stimulation for skeletal muscle function; The Yale Journal of Biology and Medicine; 85(2); pp. 201-215; Jun. 2012.
Ferreira et al., 2019, MDS evidence-based review of treatments for essential tremor, Movement Disorders, 34(7):950-958.
Fiorentino et al., 2011, Self calibrating wearable active running asummetry measurement and correction, Journal of Control Engineering and Applied Informatics, 13(2):3-8.
Fuentes et al.; Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach, Eur J Neurosci, vol. 32, pp. 1100-1108; Oct. 2010 (author manuscript; 19 pgs.).
Fuentes et al.; Spinal cord stimulation restores locomotion in animal models of Parkinson's disease; Science; 323; pp. 1578-1582; Mar. 2009.
Gallego et al.; A neuroprosthesis for tremor management through the control of muscle co-contraction; Journal of Neuroengineering and Rehabilitation; vol. 10; 36; (13 pgs); Apr. 2013.
Gallego et al.; Real-time estimation of pathological tremor parameters from gyroscope data.; Sensors; 10(3); pp. 2129-2149; Mar. 2010.
Gallego et al; A soft wearable robot for tremor assessment and suppression; 2011 IEEE International Conference on Robotics and Automation; Shanghai International Conference Center; pp. 2249-2254; May 9-13, 2011.
Gao; Analysis of amplitude and frequency variations of essential and Parkinsonian tremors; Medical & Biological Engineering & Computing; 42(3); pp. 345-349; May 2004.
Garcia et al.; Modulation of brainstem activity and connectivity by respiratory-gated auricular vagal afferent nerve stimulation in migraine patients; Pain; International Association for the Study of Pain; 2017.
Garcia-Rill, E., et al. “Arousal, motor control, and Parkinson's disease.” Translational neuroscience 6.1 pp. 198-207 (2015).
Giuffridda et al.; Clinically deployable Kinesia technology for automated tremor assessment.; Movement Disorders; 24(5); pp. 723-730; Apr. 2009.
Gracanin et al.; Optimal stimulus parameters for minimum pain in the chronic stimulatin of innervated muscle; Archives of Physical Medicine and Rehabilitation; 56(6); pp. 243-249; Jun. 1975.
Gupta et al., 2021, Exploring essential tremor: results from a large online survey, Clinical Parkinsonism & Related Disorders, 5:100101, 4 pp.
Haeri et al.; Modeling the Parkinson's tremor and its treatments; Journal of Theorectical Biology; 236(3); pp. 311-322; Oct. 2005.
Halonen et al.; Contribution of cutaneous and muscle afferent fibres to cortical SEPs following median and radial nerve stimulation in man; Electroenceph. Clin. Neurophysiol.; 71(5); pp. 331-335; Sep.-Oct. 1988.
Hao et al.; Effects of electrical stimulation of cutaneous afferents on corticospinal transmission of tremor signals in patients with Parkinson's disease; 6th International Conference on Neural Engineering; San Diego, CA; pp. 355-358; Nov. 2013.
Haubenberger et al., 2018, Essential Tremor, The New England Journal of Medicine, 378:1802-1810 and Supplementary Appendix.
Hauptmann et al.; External trial deep brain stimulation device for the application of desynchronizing stimulation techniques; Journal of Neural Engineering; 6; 12 pgs.; Oct. 2009.
Heller et al.; Automated setup of functional electrical stimulation for drop foot using a novel 64 channel prototype stimulator and electrode array: Results from a gait-lab based study; Medical Engineering & Physic; 35(1); pp. 74-81; Jan. 2013.
Hellwig et al., Feb. 17, 2001, Tremor-correlated cortical activity in essential tremor, The Lancet, 357:519-523.
Henry Dreyfuss Associates; The Measure of Man and Woman: Human Factors in Design (Revised Edition); John Wiley & Sons, New York; pp. 10-11 and 22-25; Dec. 2001.
Hernan, Miguel, et al. “Alcohol Consumption and the Incidence of Parkinson's Disease.” May 15, 2003. Annals of Neurology. vol. 54. pp. 170-175.
Hernandez-Martin et al., 2021, High-fidelity transmission of high-frequency burst stimuli from peripheral nerve to thalamic nuclei in children with dystonia, Scientific Reports, 11:8498, 9 pp.
Hua et al.; Posture-related oscillations in human cerebellar thalamus in essential tremor are enabled by voluntary motor circuits; J Neurophysiol; 93(1); pp. 117-127; Jan. 2005.
Huang, et al.; Theta burst stimulation report of the human motor cortex; Neuron, vol. 45, 201-206, Jan. 20, 2005.
Hubeaux, Katelyne, et al. “Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence.” The Journal of urology 178.6 (2007): 2483-2487.
Hubeaux, Katelyne, et al. “Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome.” Neurourology and urodynamics 30.8 (2011): 1467-1472.
Inoue et al. “Stretchable human interface using a conductive silicone elastomer containing silver fillers.” Consumer Electronics, 2009. ISCE'09. IEEE 13th International Symposium on. IEEE, 2009.
Isaacson et al., 2020, Prospective home-use study on non-invasive neuromodulation therapy for essential tremor, Tremor and Other Hyperkinetic Movements, 10(1):29, pp. 1-16.
Jacks et al.; Instability in human forearm movements studied with feed-back-controlled electrical stimulation of muscles; Journal of Physiology; 402; pp. 443-461; Aug. 1988.
Jobges et al.; Vibratory proprioceptive stimulation affects Parkinsonian tremor; Parkinsonism & Related Disorders; 8(3); pp. 171-176; Jan. 2002.
Joundi et al.; Rapid tremor frequency assessment with the iPhone accelerometer.; Parkinsonism & Related Disorders; 17(4); pp. 288-290; May 2011.
Kim et al.: Adaptive control of movement for neuromuscular stimulation-assisted therapy in a rodent model; IEEE Trans on Biomedical Engineering,; 56(2); pp. 452-461; Feb. 2009.
Krauss et al.; Chronic spinal cord stimulation in medically intractable orthostatic tremor; J Neurol Neurosurg Psychiatry; 77(9); pp. 1013-1016; Sep. 2006.
Krishnamoorthy et al., 2008, Gait Training After Stroke: A Pilot Study Combining a Gravity-Balanced Orthosis, Functional Electrical Stimulation, and Visual Feedback, Journal of Neurologic Physical Therapy, 32(4):192-202.
Kuhn et al.; Array electrode design for transcutaneous electrical stimulation a simulation study; Medical Engineering & Physics; 31 (8); pp. 945-951; Oct. 2009.
Kuhn et al.; The Influence of Electrode Size on Selectivity and Comfort in Transcutaneous Electrical Stimulation of the Forearm; Neural Systems and Rehabilitation Engineering, IEEE Transactions on; 18(3); pp. 255-262; Jun. 2010.
Kunz, Patrik, et al. “5 kHz transcranial alternating current stimulation: lack of cortical excitability changes when grouped in a theta burst pattern.” Frontiers in Human Neuroscience 10 (2016): 683.
Lagerquist et al.: Influence of stimulus pulse width on M-waves, H-reflexes, and torque during tetanic low-intensity neuromuscular stimulation, Muscle & Nerve, 42(6), pp. 886-893; Dec. 2010.
Laroy et al.; The sensory innervation pattern of the fingers; J. Neurol.; 245 (5); pp. 294-298; May 1998.
Lee et al.; Resetting of tremor by mechanical perturbations: A comparison of essential tremor and parkinsonian tremor; Annals of Nuerology; 10(6); pp. 523-531; Dec. 1981.
Legon et al.; Pulsed ultrasound differentially stimulates somatosensory circuits in humans as indicated by EEG and fMRI; PLoS ONE; 7(12); e51177; 14 pgs.; Dec. 2012.
Liao, Wen-Chien, et al. “A noninvasive evaluation of autonomic nervous system dysfunction in women with an overactive bladder.” International Journal of Gynecology & Obstetrics 110.1 (2010): 12-17.
Lin et al., 2018, Noninvasive neuromodulation inessential tremor demonstrates relief in a sham-controlled pilot trial, Movement Disorders, 33(7):1182-1183.
Llinas et al., Dec. 21, 1999, Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography, PNAS, 96(26):15222-15227.
Lourenco et al.; Effects produced in human arm and forearm motoneurones after electrical stimulation of ulnar and median nerves at wrist level; Experimental Brain Research; 178(2); pp. 267-284; Apr. 2007.
Lyons et al., 2021, Essential tremor in adult patients, International Essential Tremor Foundation, 16 pp.
Malek et al.; The utility of electromyography and mechanomyography for assessing neuromuscular function: a noninvasive approach; Phys Med Rehabil in N Am; 23(1); pp. 23-32; Feb. 2012.
Mamorita et al.; Development of a system for measurement and analysis of tremor using a three-axis accelerometer; Methods Inf Med; 48(6); pp. 589-594; epub Nov. 2009.
Maneski et al.; Electrical Stimulation for suppression of pathological tremor; Med Biol Eng Comput; 49(10); pp. 1187-1193; Oct. 2011.
Marsden et al.; Coherence between cerebellar thalamus, cortex and muscle in man; Brain; 123; pp. 1459-1470; Jul. 2000.
Marshall, Ryan, et al. “Bioelectrical stimulation for the reduction of inflammation in inflammatory bowel disease.” Clinical Medicine Insights: Gastroenterology 8 (2015): CGast-S31779.
McAuley et al.; Physiological and pathological tremors and rhythmic central motor control; Brain; 123(Pt 8); pp. 1545-1567; Aug. 2000.
McIntyre et al.; Finite element analysis of current-density and electric field generated by metal microelectrodes; Annals of Biomedical Engineering; 29(3); pp. 227-235; Mar. 2001.
Meekins et al.; American Association of Neuromuscular & Electrodiagnostic Medicine evidenced-based review: use of surface electromyography in the diagnosis and study of neuromuscular disorders; Muscle Nerve 38(4); pp. 1219-1224; Oct. 2008.
Mehnert, Ulrich, et al. “Heart rate variability: an objective measure of autonomic activity and bladder sensations during urodynamics.” Neurourology and urodynamics 28.4 (2009): 313-319.
Miguel et al.; Alcohol consumption and the incidence of Parkinson's disease; Ann. Neurol.; 54(2); pp. 170-175; May 15, 2003.
Miller et al.; Multiplexed microneedle-based biosensor array for characterization of metabolic acidosis; Talanta; 88; pp. 739-742; Jan. 2012 (author manuscript; 13 pgs.).
Miller et al.; Neurostimulation in the treatment of primary headaches; Pract Neurol; Apr. 11, 2016;16:pp. 362-375.
Milne et al.; Habituation to repeated in painful and non-painful cutaneous stimuli: A quantitative psychophysical study; Experimental Brain Research; 87(2); pp. 438-444; Nov. 1991.
Mommaerts et al.; Excitation and nerve conduction; in Comprehensive Human Physiology; Springer Berlin Heidelberg; Chap. 13; pp. 283-294; Mar. 1996.
Mones et al.; The response of the tremor of patients with Parkinsonism to peripheral nerve stimulation; J Neurology, Neurosurgery, and Psychiatry; 32(6); pp. 512-518; Dec. 1969.
Morgante et al.: How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus?; Results of a Questionnaire, Partkinsonism Relat Disord; 13; pp. 528-531; Dec. 2007.
Munhoz et al; Acute effect of transcutaneous electrical nerve stimulation on tremor; Movement Disorders; 18(2); pp. 191-194; Feb. 2003.
Nardone et al.; Influences of transcutaneous electrical stimulation of cutaneous and mixed nerves on subcortical somatosensory evoked potentials; Electroenceph. Clin. Neurophysiol.; 74(1); pp. 24-35; Jan.-Feb. 1989.
Nonis et al.; Evidence of activation of vagal afferents by non-invasive vagus nerve stimulation: An electrophysiological study in healthy volunteers; Cephalalgia; pp. 1285-1293; vol. 37(13); Mar. 28, 2017.
Pahwa et al., 2018, An acute randomized controlled trial of noninvasive peripheral nerve stimulation in essential tremor, Neuromodulation, 22:537-545.
Peng et al., 2015, Flexible dry electrode based on carbon nanotube/plymer hybrid micorpillars for biopotential recording, Sensor and Actuatora A: Physical, 235:48-65.
Perez et al.; Patterned Sensory Stimulation Induces Plasticity in Reciprocal la Inhibition in Humans; The Journal of Neuroscience; 23(6); pp. 2014-2018; Mar. 2003.
Perez-Reyes, Jan. 2003, Molecular physiology of low-voltage-activated T-type calcium channels, Physiol. Rev. 83:117-161.
Perlmutter et al.; Deep brain stimulation; Ann Rev Neurosci; 29; pp. 229-257; Jul. 2006.
Popovic-Bijelic et al. “Multi-field surface electrode for selective electrical stimulation.” Artificial organs 29.6 (2005): 448-452.
Prochazka et al.; Attenuation of pathological tremors by functional electrical stimulation I: Method; Annals of Biomedical Engineering; 20(2); pp. 205-224; Mar. 1992.
Pulliam et al.; Continuous in-home monitoring of essential tremor; Parkinsonism Relat Disord; 20(1); pp. 37-40; Jan. 2014.
Quattrini et al.; Understanding the impact of painful diabetic neuropathy; Diabetes/Metabolism Research and Reviews; 19, Suppl. 1; pp. S2-S8; Jan.-Feb. 2003.
Rocon et al.; Design and validation of a rehabilitation robotic exoskeleton for tremor assessment and suppression; IEEE Trans Neural Sys and Rehab Eng.; 15(3); pp. 367-378; Sep. 2007.
Sigrist et al., 2012. Augmented visual, auditory, haptic, and multimodal feedback in motor learning: A review. Psychonomic Bulletin & Review, 20(1):21-53.
Silverstone et al.; Non-Invasive Neurostimulation in the Control of Familial Essential Tremor Using the Synaptic Neuromodulator; Conference Proceedings, International Functional Electrical Stimulation Society (IFES); Ed. Paul Meadows; 3 pgs.; May 1999.
Singer et al.; The effect of EMG triggered electrical stimulation plus task practice on arm function in chronic stroke patients with moderate-severe arm deficits; Restor Neurol Neurosci; 31(6); pp. 681-691; Oct. 2013.
Solomonow et al., 1998, Studies toward spasticity suppression with hight frequency electrical stimulation, Orthopedics, 7(8):1284-1288.
Straube et al.; Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial; The Journal of Headache and Pain (2015) 16:63.
Takanashi et al.; A functional MRI study of somatotopic representation of somatosensory stimulation in the cerebellum; Neuroradiology; 45(3); pp. 149-152; Mar. 2003.
Tass et al.; Coordinated reset has sustained aftereffects in Parkinsonian monkeys; Ann Neurol; 72(5); pp. 816-820; Nov. 2012.
Tass et al.; Counteracting tinnitus by acoustic coordinated reset neuromodulation; Restorative neurology and Neuroscience; 30(2); pp. 137-159; Apr. 2012.
Tass; A Model of desynchronizing deep brain stimulation with a demand-controlled coordinated reset of neural subpopulations; Bioi Cybern; 89(2); pp. 81-88; Aug. 2003.
Thomas et al.; A review of posterior tibial nerve stimulation for faecal incontinence; Colorectal Disease; 2012 The Association of Coloproctology of Great Britain and Ireland. 15, pp. 519-526; Jun. 25, 2012.
Tolosa et al.; Essential tremor: treatment with propranolol; Neurology; 25(11); pp. 1041; Nov. 1975.
Tracey; The inflammatory reflex; Nature; vol. 420; pp. 853-859; Dec. 19/26, 2002.
Treager; Interpretation of skin impedance measurements; Nature; 205; pp. 600-601; Feb. 1965.
Valente; Novel methods and circuits for field shaping in deep brain stimulation; Doctoral thesis, UCL (University College London); 222 pgs.; 2011.
Vitton et al.; Transcutaneous posterior tibial nerve stimulation for fecalIncontinence in inflammatory bowel disease patients: a therapeutic option?; Inflamm Bowel Dis; vol. 15, No. 3, Mar. 2009; pp. 402-405.
Von Lewinski et al.; Efficacy of EMG-triggered electrical arm stimulation in chronic hemiparetic stroke patients; Restor Neurol Neurosci; 27(3); pp. 189-197; Jun. 2009.
Wardman et al.; Subcortical, and cerebellar activation evoked by selective stimulation of muscle and cataneous afferents: an fMRI study; Physiol. Rep.; 2(4); pp. 1-16; Apr. 2014.
Wiestler et al.; Integration of sensory and motor representations of single fingers in the human; J. Neurophysiol.; 105(6); pp. 3042-3053; Jun. 2011.
Woldag et al.; Evidence-based physiotherapeutic concepts for improving arm and hand function in stroke patients R A review; J Neurol; 249(5); pp. 518-528; May 2002.
Woolf et al.; Peripheral nerve injury triggers central sprouting of myelinated afferents; Nature; 355(6355); pp. 75-78; Jan. 1992.
Yarnitsky et al.; Nonpainful remote electrical stimulation alleviates episodic migraine pain; Neurology 88; pp. 1250-1255; Mar. 28, 2017.
Yeh et al., “Intensity sensitive modulation effect of theta burst form of median nerve stimulation on the monosynaptic spinal reflex.” Neural plasticity 2015 (2015) in 8 pages.
Yilmaz, Ozlem O., et al. “Efficacy of EMG-biofeedback in knee osteoarthritis.” Rheumatology international 30.7 (2010): 887-892.
Zhang et al.; Neural oscillator based control for pathological tremor suppression via functional electrical stimulation; Control Engineering Practice; 19(1); pp. 74-88; Jan. 2011.
Zorba et al.; Overactive bladder and the pons; Rize University, Medical Faculty, Department of Urology; 123-124; Undated.
Zwarts et al.; Multichannel surface EMG: basic aspects and clinical utility; Muscle Nerve; 28(1); pp. 1-17; Jul. 2003.
Knutson et al., Nov. 2015, Neuromuscular electrical stimulation for motor restoration in hemiplegia, Phys. Med. Rehabil. Clin. N. Am., 26(4):729-745.
Amarenco et al. “Urondynamic Effect of Acute Transcutaneous Posterior Tibial Nerve Stimulation in Overactive Bladder” Journal of Urology vol. 169, 2210-2215 (Jun. 2003).
Buschbacher et al.; Manual of nerve conduction series; 2nd edition; Demos Medical Publishing, LLC; 2006 (part 2, p. #143 to #299).
Fred E. Govier, et al., “Percutaneous Afferent Neuromodulation for the Refractory Overactive Bladder: Results of a Multicenter Study,” 165 J. Urology 1193-1198 (Apr. 2001).
H.C. Klingler, et al., “Use of Peripheral Neuromodulation of the S3 Region for Treatment of Detrusor Overactivity: A Urodynamicbased Study,” Urology 56:766-771, 2000.
Knutson et al., Neuromuscular Electrical Stimulation for Motor Restoration in Hemiplegia. Phys Med Rehabil Clin N A,. Nov. 2015; 26(4): 729-745. Published online Aug. 14, 2015. Doi: 10.1016/j.pmr.2015.06.002.
Michael R. Van Balken, et al., “Posterior Tibial Nerve Stimulation as Neuromodulative Treatment of Lower Urinary Track Dysfunction,” 166 J. Urology 914-918 (Sep. 2001).
Popovi Maneski et al.; Electrical stimulation for the suppression of pathological tremor; Medical & Biological Engineering & Computing; 49(10); pp. 1187-1193; Oct. 2011.
Wallerberger, Apr. 4, 2019, Efficient Estimation of Autocorrelation Spectra, ArXiv.org, https://arxiv.org/abs/1810.05079.
Cala Trio Health Care Professional Guide (Jul. 2020).
Cala Trio Health Care Professional Guide (Nov. 2019).
Chang, M.D., Qwang-Yuen et al., Effect of Electroacupuncture and Transcutaneous Electrical Nerve Stimulation at Hegu (LI.4) Acupuncture Point on the Cutaneous Reflect, 27 Acupuncture & Electro-Therapeutics Res., Int. J. 191-202 (2002).
Javidan, et al, Attenuation of Pathological Tremors by Functional Electrical Stimulation II: Clinical Evaluation, 20 Annals of Biomedical Engineering 225 (1992).
PTAB-IPR2024-00732—Exhibit 1002—Declaration of John Laughlin, M. Eng., P.E., in 109 pages.
PTAB-IPR2024-00732—Petition for Inter Partes Review of U.S. Pat. No. 10,786,669, filed Mar. 29, 2024, in 101 pages.
PTAB-IPR2024-00743—Exhibit 1002—Declaration of John Laughlin, M. Eng., P.E., in 102 pages.
PTAB-IPR2024-00743—Petition for Inter Partes Review of U.S. Pat. No. 11,628,300, filed Mar. 29, 2024, in 113 pages.
Provisional Applications (1)
Number Date Country
62886218 Aug 2019 US